<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Pers Med</journal-id>
<journal-id journal-id-type="iso-abbrev">J Pers Med</journal-id>
<journal-id journal-id-type="publisher-id">jpm</journal-id>
<journal-title-group>
<journal-title>Journal of Personalized Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2075-4426</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30551677</article-id>
<article-id pub-id-type="pmc">6313785</article-id>
<article-id pub-id-type="doi">10.3390/jpm8040044</article-id>
<article-id pub-id-type="publisher-id">jpm-08-00044</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Morgan</surname>
<given-names>Stephen</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duguez</surname>
<given-names>Stephanie</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2239-9094</contrib-id>
<name>
<surname>Duddy</surname>
<given-names>William</given-names>
</name>
<xref ref-type="corresp" rid="c1-jpm-08-00044">*</xref>
</contrib>
</contrib-group>
<aff id="af1-jpm-08-00044">Northern Ireland Centre for Stratified Medicine, Altnagelvin Hospital Campus, Ulster University, Londonderry BT47 6SB, Northern Ireland, UK; <email>Morgan-S20@ulster.ac.uk</email> (S.M.); <email>s.duguez@ulster.ac.uk</email> (S.D.)</aff>
<author-notes>
<corresp id="c1-jpm-08-00044"><label>*</label>Correspondence: <email>w.duddy@ulster.ac.uk</email>; Tel.: +44-28-71-675-686</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2018</year>
</pub-date>
<volume>8</volume>
<issue>4</issue>
<elocation-id>44</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 by the authors.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Multiple genes and mechanisms of pathophysiology have been implicated in amyotrophic lateral sclerosis (ALS), suggesting it is a complex systemic disease. With this in mind, applying personalized medicine (PM) approaches to tailor treatment pipelines for ALS patients may be necessary. The modelling and analysis of molecular interaction networks could represent valuable resources in defining ALS-associated pathways and discovering novel therapeutic targets. Here we review existing omics datasets and analytical approaches, in order to consider how molecular interaction networks could improve our understanding of the molecular pathophysiology of this fatal neuromuscular disorder.</p>
</abstract>
<kwd-group>
<kwd>ALS</kwd>
<kwd>personalized medicine</kwd>
<kwd>molecular interaction networks</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-jpm-08-00044">
<title>1. Introduction</title>
<p>Amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s disease, is a progressive neuromuscular disorder. ALS is the most common form of motor neuron disease (MND) and is characterised by progressive degeneration of both upper and lower motor neurons. Symptoms associated with the disease include muscle atrophy, limb paralysis, dysphagia, dysarthria, and respiratory failure. The annual incidence rate of ALS in the European population is approximately 2–3 per 100,000 people [<xref ref-type="bibr" rid="B1-jpm-08-00044">1</xref>], with the highest incidence occurring in individuals &gt;55 years of age. Prognosis is poor, with median survival time from onset to death of around 20–48 months [<xref ref-type="bibr" rid="B2-jpm-08-00044">2</xref>]. ALS can be divided broadly into two categories, familial ALS (fALS) involving patients with a family history of disease, and sporadic ALS (sALS), involving patients with no previous family history. Cases are split approximately 90%–95% sALS and 5%–10% fALS [<xref ref-type="bibr" rid="B3-jpm-08-00044">3</xref>,<xref ref-type="bibr" rid="B4-jpm-08-00044">4</xref>]. </p>
<p>With improving technologies in genomic analysis and large-scale international collaborations, the understanding of genetic factors in fALS has improved significantly [<xref ref-type="bibr" rid="B5-jpm-08-00044">5</xref>]. Studies have been able to identify multiple ALS-associated genes, and from the discovery of the first ALS-associated gene <italic>SOD1</italic>, more than 20 genes have been attributed to the disease [<xref ref-type="bibr" rid="B6-jpm-08-00044">6</xref>,<xref ref-type="bibr" rid="B7-jpm-08-00044">7</xref>]. Pathogenic mutations have been identified in genes such as <italic>ALS2</italic>, <italic>SETX</italic>, <italic>SPG11</italic>, <italic>FUS</italic>, <italic>VAPB</italic>, <italic>ANG</italic>, <italic>TARDBP</italic>, <italic>FIG4</italic>, <italic>OPTN</italic>, <italic>VCP</italic>, <italic>UBQLN2</italic>, and <italic>C9orf72</italic> [<xref ref-type="bibr" rid="B8-jpm-08-00044">8</xref>,<xref ref-type="bibr" rid="B9-jpm-08-00044">9</xref>]. Multiple cell types have been postulated to play a role in pathology, such as muscle satellite cells, mitochondria, astrocytes, and microglia [<xref ref-type="bibr" rid="B10-jpm-08-00044">10</xref>,<xref ref-type="bibr" rid="B11-jpm-08-00044">11</xref>,<xref ref-type="bibr" rid="B12-jpm-08-00044">12</xref>,<xref ref-type="bibr" rid="B13-jpm-08-00044">13</xref>].</p>
<p>Riluzole and edaravone are currently the only two approved drug therapeutics available in the treatment of ALS and are observed to have a modest efficacy. Clinical trials involving riluzole treatment in ALS populations have indicated an improvement in survival of ALS patients compared to placebo controls [<xref ref-type="bibr" rid="B14-jpm-08-00044">14</xref>,<xref ref-type="bibr" rid="B15-jpm-08-00044">15</xref>]. Subsequent reviews have identified that riluzole can extend the median survival time of ALS patients by around 2–3 months [<xref ref-type="bibr" rid="B16-jpm-08-00044">16</xref>]. The cost effectiveness of the drug, as well as the ability to treat the functional consequences of disease, such as muscle strength and bulbar or limb function, have been extensively studied [<xref ref-type="bibr" rid="B17-jpm-08-00044">17</xref>]. Clinical trials involving edaravone treatment in ALS populations were originally unable to identify any statistically significant benefit between treatment groups and placebo groups [<xref ref-type="bibr" rid="B18-jpm-08-00044">18</xref>]. Post hoc analysis subsequently identified a subpopulation of ALS patients with well-defined early stage ALS that appeared to respond to treatment with a reduction in the deterioration of their ALS Functional Rating score (ALSFRS-R) compared to placebo [<xref ref-type="bibr" rid="B19-jpm-08-00044">19</xref>,<xref ref-type="bibr" rid="B20-jpm-08-00044">20</xref>]. The efficacy of edaravone was only apparent in a subset of ALS patients with early stage ALS, and it is believed that any benefits observed would not translate to the whole ALS population [<xref ref-type="bibr" rid="B21-jpm-08-00044">21</xref>]. The overall limited efficacy of both these approved ALS drugs highlights the necessity of developing more effective therapeutics.</p>
<p>Biomarkers are laboratory-measurable biological characteristics that can be attributed to a certain physiological or pathological process. Within ALS, the early diagnosis of patients remains difficult due to the phenotypic overlap between the disease and various oer motor neuron diseases. Biomarkers have the potential to provide more accurate diagnoses of ALS patients and to help stratify the ALS patient population into groups of responders to therapeutics, to act as prognostic markers in disease progression, and to lead us toward possible drug targets. The value of biomarkers in ALS has been demonstrated in previous publications. For example, studies have shown that cerebrospinal fluid (CSF) diagnostic assays can provide a suitable diagnostic tool for distinguishing ALS patients from control groups in their respective study populations. A study involving 41 ALS patients and 33 neurological disease controls was able to define a diagnostic assay with 87.5% sensitivity and 91.2% specificity, using the top five differentially expressed proteins between the two test groups (IL-10, IL-6, GM-CSF, IL-2, and IL-15) [<xref ref-type="bibr" rid="B22-jpm-08-00044">22</xref>]. A separate study identified phosphorylated neurofilament heavy chain and complement C3 (pNFH/C3) as optimal biomarkers for a diagnostic assay when measuring levels of cytoskeletal proteins and inflammatory markers in CSF samples of ALS subjects, disease controls, and healthy controls. The diagnostic assay was able to identify ALS patients with 87.3% sensitivity and 94.6% specificity when applied to a study population consisting of 71 ALS subjects, 52 disease controls, and 40 healthy subjects [<xref ref-type="bibr" rid="B23-jpm-08-00044">23</xref>]. However, CSF samples are relatively invasive and expensive to obtain compared to blood assays.</p>
<p>Multiple prognostic biomarkers have been identified to predict disease severity, originating from blood, muscle, CSF, and genetic factors [<xref ref-type="bibr" rid="B24-jpm-08-00044">24</xref>]. Higher pNFH levels in plasma, serum, and CSF samples have been associated with a faster decline in the ALSFRS-R score, suggesting a more rapid disease progression [<xref ref-type="bibr" rid="B25-jpm-08-00044">25</xref>]. Multiple inflammatory markers have been suggested to provide viable prognostic markers in ALS. Increased levels of wide-range C-reactive protein (wrCRP) [<xref ref-type="bibr" rid="B26-jpm-08-00044">26</xref>], high mobility group box 1 (HMGB1) autoantibody, increased granzyme B, and increased CSF IL-8 levels [<xref ref-type="bibr" rid="B22-jpm-08-00044">22</xref>,<xref ref-type="bibr" rid="B27-jpm-08-00044">27</xref>,<xref ref-type="bibr" rid="B28-jpm-08-00044">28</xref>] have all been implicated in correlating with a more rapid decline in the ALSFRS-R score. The number of genetic alterations associated with ALS continues to grow. Prognostically, the presence of some genetic variants indicates susceptibility to and increased severity of ALS. The most frequently known genetic cause of ALS is the hexanucleotide repeat (GGGGCC) expansion in the first intron of <italic>C9ORF72</italic> [<xref ref-type="bibr" rid="B22-jpm-08-00044">22</xref>]. Patients exhibiting this repeat expansion are characterised by a lower age of onset and a shorter survival time [<xref ref-type="bibr" rid="B29-jpm-08-00044">29</xref>,<xref ref-type="bibr" rid="B30-jpm-08-00044">30</xref>]. Numerous other genetic variants have been associated with reduced survival in the ALS population, including <italic>SLC11A2</italic>, <italic>UNC13A</italic>, and <italic>ZNF512B</italic>, among many others [<xref ref-type="bibr" rid="B31-jpm-08-00044">31</xref>,<xref ref-type="bibr" rid="B32-jpm-08-00044">32</xref>,<xref ref-type="bibr" rid="B33-jpm-08-00044">33</xref>]. Whereas prognostic and diagnostic biomarkers have been identified in ALS, their usefulness in terms of directing drug development is currently minimal.</p>
<p>Research investigating the molecular basis of ALS aims to elucidate molecular mechanisms involved in disease pathology with the hope of yielding insights into defining viable therapeutic targets. In ALS, multiple molecular mechanisms have been suggested. Glutamate excitotoxicity is believed to cause neuronal death either via abnormally high presynaptic neuron activity, impaired response to excitatory stimuli in the postsynaptic neuron, or a combination of both [<xref ref-type="bibr" rid="B34-jpm-08-00044">34</xref>], and is believed to be a therapeutic target of riluzole. Examples include increased extracellular glutamate levels due to reduced clearance via glutamate transporters such as the excitatory amino acid transporter 2 (<italic>EAAT2</italic>) expressed on astrocytes [<xref ref-type="bibr" rid="B35-jpm-08-00044">35</xref>,<xref ref-type="bibr" rid="B36-jpm-08-00044">36</xref>], or increased synaptic release of glutamate via endoplasmic reticulum stress (ER) [<xref ref-type="bibr" rid="B37-jpm-08-00044">37</xref>]. Mitochondrial dysfunction and death is considered an important component in ALS pathogenesis. Super oxide dismutase (<italic>SOD1</italic>) mutations have been observed to result in the accumulation of mutant SOD1 aggregates in mitochondria, causing mitochondrial damage and subsequent motor neuron death [<xref ref-type="bibr" rid="B38-jpm-08-00044">38</xref>,<xref ref-type="bibr" rid="B39-jpm-08-00044">39</xref>]. Morphological abnormalities in mitochondria and the presence of fusion and fission proteins have all been documented to disrupt normal mitochondria function in ALS [<xref ref-type="bibr" rid="B40-jpm-08-00044">40</xref>]. Reactive oxygen species (<italic>ROS</italic>) accumulation has been linked to ALS due to reduced clearance by mutant SOD1 [<xref ref-type="bibr" rid="B41-jpm-08-00044">41</xref>]. Protein toxicities in the form of TAR DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), optineurin (OPTN), and ubiquilin-2 (UBQLN2) aggregate in motor neuron and glial cells [<xref ref-type="bibr" rid="B42-jpm-08-00044">42</xref>,<xref ref-type="bibr" rid="B43-jpm-08-00044">43</xref>,<xref ref-type="bibr" rid="B44-jpm-08-00044">44</xref>,<xref ref-type="bibr" rid="B45-jpm-08-00044">45</xref>,<xref ref-type="bibr" rid="B46-jpm-08-00044">46</xref>]. This list of mechanisms implicated in ALS is far from exhaustive, and many more mechanisms have been suggested. Considering the multitude of genes identified as associated with fALS and the varying molecular mechanisms described, ALS in many cases may be a multigenic systemic disease. As a result, applying a personalized approach to molecular data could provide a benefit to ALS patients if their specific mechanism of disease can be determined and therapies relevant to these disease mechanisms can be applied. The use of molecular interaction networks can aid in the understanding of disease mechanisms associated with ALS and can identify genes and biological pathways that may be perturbed by these mechanisms, to provide possible therapeutic targets.</p>
<p>Personalized medicine is the concept of tailoring treatment to the individual patient. With advancements in “omics” technologies (e.g., genome, proteome, metabolome), the ability to comprehensively define an individual’s omics profile, has illustrated how biologically heterogeneous we are [<xref ref-type="bibr" rid="B47-jpm-08-00044">47</xref>]. Understanding how a person’s omics profile can influence their disease phenotype, response to treatment, and prognosis can allow clinicians to identify the most efficient and beneficial treatment plan for patients. Heritable factors and the variability of the underlying cause of disease can attribute to varying drug responses observed in patient populations [<xref ref-type="bibr" rid="B48-jpm-08-00044">48</xref>].</p>
<p>An example of how personalised medicine approaches at the molecular level can be implemented to improve patient care is in cystic fibrosis (CF). Mutations in the CF transmembrane conductance regulator (<italic>CFTR</italic>) gene have been identified as the root cause for the disease [<xref ref-type="bibr" rid="B49-jpm-08-00044">49</xref>,<xref ref-type="bibr" rid="B50-jpm-08-00044">50</xref>,<xref ref-type="bibr" rid="B51-jpm-08-00044">51</xref>]. Mutations in the <italic>CFTR</italic> gene result in a dysfunctional CFTR protein. In the airway epithelial cells, this results in viscous mucous secretions due to inadequate chloride transport. This results in chronic infection and inflammation, leading to respiratory failure [<xref ref-type="bibr" rid="B52-jpm-08-00044">52</xref>]. In CF, there are currently three approved drugs that target specific genetic mutations in the CF population. Ivacaftor targets patients with at least one allele of the <italic>G551D CFTR</italic> gating mutation [<xref ref-type="bibr" rid="B53-jpm-08-00044">53</xref>], lumacaftor/ivacaftor and tezacaftor/ivacaftor are combination treatments in the treatment of the most common <italic>CFTR</italic> mutation, Phe508del [<xref ref-type="bibr" rid="B54-jpm-08-00044">54</xref>,<xref ref-type="bibr" rid="B55-jpm-08-00044">55</xref>,<xref ref-type="bibr" rid="B56-jpm-08-00044">56</xref>]. This example highlights the potential benefit of treating patients based on their personal genomic profile. Although the treatments are not generalizable across the whole population, they are able to produce significant benefits to the strata of patients they target [<xref ref-type="bibr" rid="B57-jpm-08-00044">57</xref>,<xref ref-type="bibr" rid="B58-jpm-08-00044">58</xref>,<xref ref-type="bibr" rid="B59-jpm-08-00044">59</xref>]. Since many genes are implicated in ALS, a single therapeutic target to treat the whole patient population may not be feasible. With this in mind, a personalized medicine approach may be needed to effectively develop therapeutics for the ALS population.</p>
<p>Within living organisms, a single protein or other biomolecule will rarely act alone to effect a given function. Instead, there is a complex series of interactions between multiple biomolecules that contributes to a biological process [<xref ref-type="bibr" rid="B60-jpm-08-00044">60</xref>]. These interactions can include protein-protein binding, gene co-expression, RNA interactions, and many other types of molecular functional association. Functional associations can be represented using molecular interaction networks (MINs), with nodes denoting molecules and edges denoting the interactions between nodes. Biological networks have been identified as scale-free networks that follow a power law distribution [<xref ref-type="bibr" rid="B61-jpm-08-00044">61</xref>]. This indicates that biological networks are not randomly connected, but instead exhibit a definite architecture related to biological processes contained within the interactions. Studying the structure and topology of MINs can help identify biomolecules that are involved in biological processes and elucidate which biomolecules or processes are dysfunctional in disease [<xref ref-type="bibr" rid="B62-jpm-08-00044">62</xref>,<xref ref-type="bibr" rid="B63-jpm-08-00044">63</xref>,<xref ref-type="bibr" rid="B64-jpm-08-00044">64</xref>]. Identifying disease-implicated modules in networks will aid in narrowing the search for effective drug targets or disease biomarkers [<xref ref-type="bibr" rid="B65-jpm-08-00044">65</xref>]. With a network view of a disease phenotype, multitarget therapies can be implemented to target dysfunctional processes that may be impractical to resolve with a single drug therapeutic [<xref ref-type="bibr" rid="B66-jpm-08-00044">66</xref>]. Since ALS may in many cases be a multigenic complex systemic disease, MIN approaches are particularly relevant, as they could potentially identify one or more network clusters that are consistently associated with pathology but within which only a smaller subset of genes or other biomolecules are affected in any one patient (<xref ref-type="fig" rid="jpm-08-00044-f001">Figure 1</xref>).</p>
<p>In this review, we highlight the current applications of MINs in ALS and how further approaches might be applied toward personalized medicine in future analyses.</p>
</sec>
<sec id="sec2-jpm-08-00044">
<title>2. Omics Data in Amyotrophic Lateral Sclerosis</title>
<p>It would be impractical to review all of the many available omics datasets relevant to ALS, but here we examine a few key studies.</p>
<sec id="sec2dot1-jpm-08-00044">
<title>2.1. Transcriptomic</title>
<p>The Gene Expression Omnibus (GEO, <uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</uri>) and the ArrayExpress Archive (<uri xlink:href="http://www.ebi.ac.uk/arrayexpress">http://www.ebi.ac.uk/arrayexpress</uri>) are international repositories for functional genomic data including microarrays, next-generation sequencing, or other high-throughput methods [<xref ref-type="bibr" rid="B67-jpm-08-00044">67</xref>,<xref ref-type="bibr" rid="B68-jpm-08-00044">68</xref>]. A search of the terms “ALS” or “amyotrophic lateral sclerosis” revealed more than 117 human studies of gene expression data in GEO, and 131 in ArrayExpress. These transcriptomic studies have shown, among other things, differing profiles between ALS patients, disease mimic syndromes, and healthy controls, and have enabled comparisons of transcriptomic profiles within ALS variations. One such study compared <italic>C9ORF72</italic> ALS frontotemporal dementia (FTD) patients to sporadic ALS/FTD patients. The results suggested that between these two variations of ALS, the transcriptomic profiles were comparatively similar, suggesting a common mechanism of disease [<xref ref-type="bibr" rid="B69-jpm-08-00044">69</xref>]. This study highlights the potential for application of personalized medicine in ALS, as varying forms of the disease are being defined and analysed to determine mechanistic differences, or in this case similarities. Furthermore, by understanding different subtypes of ALS and their mechanistic underpinnings, it provides the opportunity for the development of subtype-specific therapies. Of particular relevance to MIN approaches, gene expression data can be represented as coexpression networks. Identifying modules of genes that are coexpressed can be suggestive of genetic interactions at a functional level [<xref ref-type="bibr" rid="B70-jpm-08-00044">70</xref>,<xref ref-type="bibr" rid="B71-jpm-08-00044">71</xref>]. Applications of gene coexpression network analysis have been successfully applied in ALS. Multiple gene coexpression studies have revealed several pathways believed to be implicated in ALS, including cell adhesion, calcium ion binding, inflammatory processes, and tumour necrosis factor (TNF) signalling [<xref ref-type="bibr" rid="B72-jpm-08-00044">72</xref>,<xref ref-type="bibr" rid="B73-jpm-08-00044">73</xref>,<xref ref-type="bibr" rid="B74-jpm-08-00044">74</xref>,<xref ref-type="bibr" rid="B75-jpm-08-00044">75</xref>,<xref ref-type="bibr" rid="B76-jpm-08-00044">76</xref>,<xref ref-type="bibr" rid="B77-jpm-08-00044">77</xref>]. Brohawn et al. took gene expression data gathered from seven ALS spinal cord samples and eight control spinal cord samples [<xref ref-type="bibr" rid="B78-jpm-08-00044">78</xref>]. A post-filtered list of expressed genes was forwarded for weighted gene coexpression network analysis (WGCNA), which can be used to generate a gene coexpression network and to predict modules of highly associated genes that can be mapped to phenotypic traits. The authors were able to identify a module of coexpressed genes that was significantly associated with the ALS phenotype. They identified the hub genes present in this module and, with supplementary data, were able to select a gene, <italic>TNFAIP2</italic>, that when put forward for molecular testing appeared to induce motor neuron death when overexpressed. A limitation in this type of analysis is determining whether the gene coexpression module represents a causative factor in pathology or a consequence of downstream dysregulated physiological processes.</p>
</sec>
<sec id="sec2dot2-jpm-08-00044">
<title>2.2. Genomic</title>
<p>In terms of understanding disease, genome wide association studies (GWAS) are used to identify functional genetic variants in disease populations that are not observed, or are observed less frequently, in the genomes of healthy controls. The National Human Genome Research Institute (NHGRI) GWAS Catalog (<uri xlink:href="https://www.ebi.ac.uk/gwas">https://www.ebi.ac.uk/gwas</uri>) is a publicly available database of manually curated GWAS published data. It provides an interface that allows users to filter for gene-specific or condition-specific genetic variant associations [<xref ref-type="bibr" rid="B79-jpm-08-00044">79</xref>]. From the GWAS Catalog resource, a list of ALS-associated genetic variants can be extracted: It currently contains &gt;300 ALS-associated genetic variants. In addition, the ALS Online Database (ALSoD at <uri xlink:href="http://alsod.iop.kcl.ac.uk">http://alsod.iop.kcl.ac.uk</uri>) is a freely available resource containing genetic variant associations relevant to ALS only [<xref ref-type="bibr" rid="B80-jpm-08-00044">80</xref>]. From the ALSoD, various lists of ALS-associated genetic variants can be retrieved, including lists of subpopulation genetic variant frequencies compared to the 1000 genomes reference. Studies involving a GWAS have the purpose of identifying potential biomarkers in ALS that may provide greater insight into disease pathology. A recent study of 20,806 ALS cases and 59,804 controls identified <italic>KIF5A</italic> as an ALS-associated gene [<xref ref-type="bibr" rid="B81-jpm-08-00044">81</xref>] One study based on 250 sALS cases and 250 control cases from Chinese Han populations (CHP) was able to confirm the presence of five previously reported genetic variant loci present in other ALS populations as well as identifying eight novel genetic variant loci. [<xref ref-type="bibr" rid="B81-jpm-08-00044">81</xref>,<xref ref-type="bibr" rid="B82-jpm-08-00044">82</xref>,<xref ref-type="bibr" rid="B83-jpm-08-00044">83</xref>]. The inclusion of genetic variants into analyses of MINs could help to identify common pathways in ALS or detect novel genetic associations to a known disease mechanism.</p>
</sec>
<sec id="sec2dot3-jpm-08-00044">
<title>2.3. Proteomic</title>
<p>At the time of writing, the Proteomics Identification (PRIDE) Archive database (<uri xlink:href="https://www.ebi.ac.uk/pride/archive">https://www.ebi.ac.uk/pride/archive</uri>) [<xref ref-type="bibr" rid="B84-jpm-08-00044">84</xref>] included 10 Proteomic studies of ALS involving human samples. One study identified 806 proteins that were significantly reduced in <italic>C9ORF72</italic> ALS-induced pluripotent stem cells (iPSCs) compared to control iPSCs [<xref ref-type="bibr" rid="B85-jpm-08-00044">85</xref>]. Gene ontology enrichment analysis of these proteins suggested abnormalities in oxidative phosphorylation and mitochondrial ribosomes. Another study specifically identified the protein-protein interaction (PPI) network of Matrin 3 (MATR3), a protein known to be associated with ALS. They were able to identify a deletion of the RNA recognition motif (RRM1) on MATR3 that diminished the binding of a subset of MATR3 binding proteins and was associated with the formation of intranuclear spherical structures in live cells [<xref ref-type="bibr" rid="B86-jpm-08-00044">86</xref>]. The definition of MATR3 protein interactions provides increased coverage for PPI network databases, which can be used for MIN approaches. ALS studies comparing proteomic data between control and disease cohorts have been used to identify potential biomarkers, mainly based on analysis of the cerebral spinal fluid (CSF). These studies have been able to suggest biomarker panels for ALS diagnosis via CSF [<xref ref-type="bibr" rid="B87-jpm-08-00044">87</xref>,<xref ref-type="bibr" rid="B88-jpm-08-00044">88</xref>]. PPI databases such as STRING (<uri xlink:href="https://string-db.org">https://string-db.org</uri>), BioGRID (<uri xlink:href="https://thebiogrid.org">https://thebiogrid.org</uri>), and IntAct (<uri xlink:href="https://www.ebi.ac.uk/intact">https://www.ebi.ac.uk/intact</uri>) all contain data linking interacting proteins [<xref ref-type="bibr" rid="B89-jpm-08-00044">89</xref>,<xref ref-type="bibr" rid="B90-jpm-08-00044">90</xref>,<xref ref-type="bibr" rid="B91-jpm-08-00044">91</xref>] that can be used for MIN analyses. An example of this in ALS was a study in which differentially expressed genes (DEGs) between <italic>C9ORF72</italic> and control samples were first identified, and then a PPI was constructed based on the proteins encoded by these genes, using several PPI databases to define the pathways involved in the DEGs [<xref ref-type="bibr" rid="B77-jpm-08-00044">77</xref>]. The authors were able to identify hub nodes within this network and define gene ontology (GO) terms believed to play a role in <italic>C9ORF72</italic> ALS pathophysiology, including cell adhesion, biological adhesion, and cell-cell signalling processes.</p>
</sec>
<sec id="sec2dot4-jpm-08-00044">
<title>2.4. Metabolomic</title>
<p>The Human Metabolome Database (HMDB) (<uri xlink:href="http://www.hmdb.ca">http://www.hmdb.ca</uri>) provides an interface to access a curated list of metabolites known to be abnormal in one or more specific diseases [<xref ref-type="bibr" rid="B92-jpm-08-00044">92</xref>]. When searching for “ALS”, the database yields seven metabolites that have been observed to be abnormal in ALS patients: Homocysteine, L-thyronine, manganese, nitrate, picolinic acid, prostaglandin E2, and quinolinic acid [<xref ref-type="bibr" rid="B93-jpm-08-00044">93</xref>,<xref ref-type="bibr" rid="B94-jpm-08-00044">94</xref>,<xref ref-type="bibr" rid="B95-jpm-08-00044">95</xref>,<xref ref-type="bibr" rid="B96-jpm-08-00044">96</xref>,<xref ref-type="bibr" rid="B97-jpm-08-00044">97</xref>,<xref ref-type="bibr" rid="B98-jpm-08-00044">98</xref>]. A function of metabolomic data in terms of MINs could be in the construction of an interactome network representing all biomolecules and their interactions in a given cell or tissue type. In terms of personalized medicine, the use of metabolomics could help in the diagnosis and prognosis of ALS patients, for example by identifying biomarkers.</p>
</sec>
</sec>
<sec id="sec3-jpm-08-00044">
<title>3. Molecular Data and Analyses Applied to the Study of Motor Neurons</title>
<p>A critical event in the pathology of ALS is the death of motor neurons (MNs). In this field, there is a developing debate as to whether motor neuron degeneration is a cell-autonomous process or if it depends on pathologic processes emerging in other cell and tissue types. The dying forward hypothesis suggests ALS pathology initiates MN degeneration, and any subsequent muscle atrophy is a downstream effect [<xref ref-type="bibr" rid="B99-jpm-08-00044">99</xref>,<xref ref-type="bibr" rid="B100-jpm-08-00044">100</xref>], whereas the dying back hypothesis suggests initiating pathology occurs at the muscle and neuromuscular junction, and subsequent motor neuron degeneration is a downstream effect [<xref ref-type="bibr" rid="B101-jpm-08-00044">101</xref>]. Regardless of the direction of mechanism of pathology in ALS, motor neurons are pivotal in the disease mechanism and have the potential to provide biomarkers of the disease.</p>
<p>Transcriptomic analysis has been applied in many studies involving motor neurons, mainly to determine DEGs between control and disease cohorts. Examples of studies implementing transcriptomic analysis and MINs concurrently are less frequent. One such study compared the gene coexpression profiles of the ALS model of spinal motor neurons (spMN, derived from iPSCs) to fetal spinal tissues and adult spinal tissues [<xref ref-type="bibr" rid="B102-jpm-08-00044">102</xref>]. The study was able to identify that the gene coexpression profile of the spMN more closely matched the fetal spMN than adult spMNs. This may indicate that to develop a more precise ALS model, the maturation and aging process needs to be replicated. Another study involving gene coexpression, specifically in the <italic>C9ORF72</italic> GGGGCC-expanded repeat mutation population, was able to identify coexpressed modules of genes that were differentially expressed between control and ALS MNs. The study was able to define six statistically significant GO terms associated with <italic>C9ORF72</italic> ALS pathophysiology, including the cholesterol biosynthetic process and the regulation-of-glucose metabolic process [<xref ref-type="bibr" rid="B75-jpm-08-00044">75</xref>]. The authors noted that these findings support the involvement of endoplasmic reticulum (ER) stress, a process previously implicated in ALS. The ER is responsible for the correct folding of proteins, and aggregations of misfolded proteins are often observed in ALS [<xref ref-type="bibr" rid="B103-jpm-08-00044">103</xref>].</p>
<p>GWA studies have led to the association of many genetic variants associated with motor neuron dysfunction in ALS. Mutations in the fused in sarcoma/translated in liposarcoma (<italic>FUS/TLS</italic>) gene on chromosome 16 in fALS [<xref ref-type="bibr" rid="B44-jpm-08-00044">44</xref>] are believed to contribute to toxic protein aggregations in neuronal cytoplasm, similarly to the mechanism exhibited by mutant <italic>SOD1</italic> protein aggregates in ALS [<xref ref-type="bibr" rid="B104-jpm-08-00044">104</xref>,<xref ref-type="bibr" rid="B105-jpm-08-00044">105</xref>,<xref ref-type="bibr" rid="B106-jpm-08-00044">106</xref>]. Mutations in the <italic>TARDBP</italic> gene that encodes the protein <italic>TDP-43</italic> have been identified in fALS families, with <italic>TDP-43</italic> aggregation observed in upper and lower motor neurons [<xref ref-type="bibr" rid="B107-jpm-08-00044">107</xref>,<xref ref-type="bibr" rid="B108-jpm-08-00044">108</xref>,<xref ref-type="bibr" rid="B109-jpm-08-00044">109</xref>,<xref ref-type="bibr" rid="B110-jpm-08-00044">110</xref>]. An application not yet explored for ALS genetic variant data is to include these variants into MINs such as gene coexpression or PPI networks. Examples of how this approach could be beneficial include a study of Alzheimer’s disease in which genetic variants were incorporated into a tissue-specific PPI network [<xref ref-type="bibr" rid="B111-jpm-08-00044">111</xref>]. This revealed a strong indirect connection between large numbers of proteins from known AD loci, indicating a common pathological pathway. Furthermore, a study taking the genetic variants identified in sporadic autism cases was able to identify a large interconnected hub of genetic variant-associated proteins [<xref ref-type="bibr" rid="B112-jpm-08-00044">112</xref>]. Of the 126 listed autism-related variants, 49 connected at a high degree within the PPI network. Downstream analysis of this highly connected cluster was able to identify a previously implemented pathway involving beta-catenin.</p>
<p>In ALS, the majority of proteomic studies of the motor neurons have involved the analysis and comparison of the proteome of the CSF between disease and control. All proteins accumulating in CSF are not necessarily specific to upper motor neuron tissue. The accumulation of neurofilaments in CSF is suggestive of motor neuron degradation [<xref ref-type="bibr" rid="B113-jpm-08-00044">113</xref>,<xref ref-type="bibr" rid="B114-jpm-08-00044">114</xref>]. Differential neurofilament markers between control and disease have been outlined as potential diagnostic biomarkers [<xref ref-type="bibr" rid="B85-jpm-08-00044">85</xref>,<xref ref-type="bibr" rid="B86-jpm-08-00044">86</xref>,<xref ref-type="bibr" rid="B87-jpm-08-00044">87</xref>]. In a clinical setting, these biomarker panels may be of limited use for diagnostics due to the presence of ALS mimic phenotypes. A study was able to identify extremely high levels of CSF neurofilaments as suggestive of ALS, but not conclusively so [<xref ref-type="bibr" rid="B115-jpm-08-00044">115</xref>]. Such data could be used in MIN analyses of PPI networks. A study compared the DEGs from brain biopsies in schizophrenia, bipolar disorder, and major depression [<xref ref-type="bibr" rid="B116-jpm-08-00044">116</xref>]. These DEGs were mapped to a PPI network to characterize mutual protein interactions associated with these diseases. An approach such as this in ALS would be beneficial to clearly understand any differential pathology at the motor neuron level between ALS and ALS mimic conditions.</p>
<p>Metabolomic analyses in ALS, similarly to the study of the proteome, have been focused on the CSF rather than MN cells. The study of the metabolome between control and ALS populations has potential diagnostic value [<xref ref-type="bibr" rid="B117-jpm-08-00044">117</xref>,<xref ref-type="bibr" rid="B118-jpm-08-00044">118</xref>]. One study was able to identify a diagnostic profile for ALS from differential metabolite quantities compared to controls, which performed reasonably well (78.9% sensitivity, 76.5% specificity) in characterizing a test cohort [<xref ref-type="bibr" rid="B118-jpm-08-00044">118</xref>]. Whether these metabolite markers would be generalizable across ALS populations is yet to be seen. Specific metabolome data on MNs in ALS is currently lacking, and with improving coverage of metabolomics pathways, MN-specific analysis may prove beneficial in dysfunctional pathway identification.</p>
</sec>
<sec id="sec4-jpm-08-00044">
<title>4. Molecular Data and Analyses Applied to Other ALS-Related Tissues and Cellular Compartments</title>
<sec id="sec4dot1-jpm-08-00044">
<title>4.1. Muscle</title>
<p>Muscle loss of function in ALS leads to muscle atrophy and subsequent mortality, generally due to respiratory failure. Evidence of muscle involvement as an instigating role in pathology has emerged. Studies of an ALS mouse model containing the <italic>SOD1</italic><sup>G93A</sup> mutation, selectively expressed in skeletal muscle, exhibited muscle atrophy prior to any visible MN degradation [<xref ref-type="bibr" rid="B119-jpm-08-00044">119</xref>,<xref ref-type="bibr" rid="B120-jpm-08-00044">120</xref>]. Furthermore, Nogo-A, a protein encoded by the <italic>RTN4</italic> gene, is believed to inhibit neurite outgrowth and MN regeneration [<xref ref-type="bibr" rid="B121-jpm-08-00044">121</xref>]. Studies have identified a correlation between Nogo-A levels expressed in skeletal muscle and neuromuscular junction (NMJ) denervation in early ALS disease [<xref ref-type="bibr" rid="B122-jpm-08-00044">122</xref>,<xref ref-type="bibr" rid="B123-jpm-08-00044">123</xref>]. The role of muscle in ALS may be more than a victim. Understanding mechanisms involved in muscle atrophy in ALS could provide biomarkers and new therapeutic targets.</p>
<p>Gene expression analysis of skeletal muscle in ALS has identified numerous DEGs between control and ALS groups. One study of DEGs in the muscle of ALS patients, healthy controls, and ALS mimic disease patients, suggested that Myosin Binding Protein H (MyBP-H) could be a useful biomarker [<xref ref-type="bibr" rid="B124-jpm-08-00044">124</xref>]. Gene expression profiling of <italic>G86R</italic> mice was able to detect a significant change in muscle gene expression prior to any obvious signs of motor neuron degradation [<xref ref-type="bibr" rid="B125-jpm-08-00044">125</xref>]. Gene coexpression analysis on muscle tissue in ALS has yet to be reported. A study investigating differential gene coexpression between healthy and Duchenne muscular dystrophy (DMD), utilizing gene expression data from muscle biopsies, highlighted a possible utility of gene coexpression in ALS. The study found that when comparing healthy gene coexpression modules to DMD gene coexpression modules, preservation analysis could identify dysregulated processes in DMD [<xref ref-type="bibr" rid="B126-jpm-08-00044">126</xref>]. In particular, new genes linked to the known pathological DMD gene were identified, expanding knowledge of the known disease pathway. This approach could serve to identify dysregulated processes in ALS muscle compared to healthy controls.</p>
<p>Proteomic analysis of ALS skeletal muscle has identified dysregulated protein quantities between ALS muscle and healthy controls, for example in the wobbler mouse model, which identified 21 upregulated proteins and 3 downregulated proteins involved in contractile apparatus and cell stress response [<xref ref-type="bibr" rid="B127-jpm-08-00044">127</xref>]. The proteome of an ALS muscle biopsy sample may be influenced by denervation of the muscles from the MNs. As mentioned above, PPI networks represent an important resource for MIN approaches to the analysis of proteomic data. These have not yet been applied to ALS proteomic datasets, but have been used in studies of muscle pathology. For example, one study created a PPI network from 13 proteins and closely related proteins known to be dysregulated in limb girdle muscular dystrophies (LGMDs). A PPI network was constructed based on yeast 2 hybrid screening for the identification of binary protein interactions [<xref ref-type="bibr" rid="B128-jpm-08-00044">128</xref>]. The PPI network was able to detect four novel proteins, ACTN2, MYBPC1, MYOM1, and MYOM2, identified as hub proteins sharing the highest number of links with known LGMD proteins. These novel proteins are located in key locations in the sarcomere, suggesting a link between LGMD-associated proteins and sarcomere dysfunction. Building a PPI network focused on ALS-associated proteins in muscle could help identify novel proteins involved in dysregulated processes in ALS.</p>
</sec>
<sec id="sec4dot2-jpm-08-00044">
<title>4.2. Astrocytes</title>
<p>Numerous tissues and processes have been implicated in ALS pathology. One of the more widely studied cell types is the astrocyte glial subtype. Astrocytes play a pivotal role in the function of the central nervous system (CNS), with integral roles in the formation, maintenance, and elimination of synapses [<xref ref-type="bibr" rid="B129-jpm-08-00044">129</xref>]. ALS-associated misfolded proteins SOD1 and TDP-43 have been identified as aggregating in glial cells, disrupting normal physiological function [<xref ref-type="bibr" rid="B43-jpm-08-00044">43</xref>,<xref ref-type="bibr" rid="B130-jpm-08-00044">130</xref>]. Astrocytes are implicated in numerous other neurodegenerative diseases, indicating their significance in neuronal pathology [<xref ref-type="bibr" rid="B131-jpm-08-00044">131</xref>]. In an Alzheimer’s study, the astrocyte transcriptome was analysed in terms of the aging brain [<xref ref-type="bibr" rid="B132-jpm-08-00044">132</xref>]. If a “healthy” control astrocyte transcriptome could be defined, identifying DEGs between control astrocytes and ALS astrocytes could aid in the understanding of the role of astrocytes in ALS. Astrocyte-specific datasets such as transcriptomic and proteomic profiling could be used in MIN approaches to ALS, and tissue-specific data on gene or protein expression could facilitate astrocyte-specific MIN analyses.</p>
</sec>
<sec id="sec4dot3-jpm-08-00044">
<title>4.3. Mitochondria</title>
<p>Mitochondrial dysfunction has long been associated with ALS pathology, particularly in the <italic>SOD1</italic> mutation [<xref ref-type="bibr" rid="B133-jpm-08-00044">133</xref>]. Many mechanisms of mitochondrial involvement in ALS have been identified, including clearance of dysfunctional organelles, calcium binding, and induction of mitochondrial death [<xref ref-type="bibr" rid="B134-jpm-08-00044">134</xref>]. Gene expression profiling of iPSC-derived MNs from ALS fibroblasts has identified DEGs involving mitochondrial processes [<xref ref-type="bibr" rid="B135-jpm-08-00044">135</xref>].</p>
<p>The transcriptome of the “healthy” mitochondria has previously been analysed [<xref ref-type="bibr" rid="B136-jpm-08-00044">136</xref>]. Establishing DEGs between control and ALS mitochondria could provide an insight into their specific abnormalities in ALS. It would be desirable to test muscle and neuronal mitochondrial samples separately, due to tissue-specific mitochondrial gene expression. Previous studies have shown that it is possible to identify mitochondrial DEGs from blood samples [<xref ref-type="bibr" rid="B137-jpm-08-00044">137</xref>,<xref ref-type="bibr" rid="B138-jpm-08-00044">138</xref>,<xref ref-type="bibr" rid="B139-jpm-08-00044">139</xref>]. Identifying DEGs can allow for the implementation of gene coexpression network analysis. This could elucidate mitochondrial and astrocyte processes specifically dysregulated in ALS. Furthermore, constructing a unique PPI network for known mitochondrial proteins, utilizing high throughput yeast 2 hybrid methods, could allow for dysregulated processes in ALS mitochondria to be predicted [<xref ref-type="bibr" rid="B140-jpm-08-00044">140</xref>].</p>
</sec>
</sec>
<sec id="sec5-jpm-08-00044">
<title>5. Conclusions</title>
<p>Personalized medicine provides the opportunity for improved treatment strategies in disease. Utilizing omics data is vital in establishing biomarkers for improved diagnosis, prognosis, and therapeutic targets. Molecular interaction networks represent a powerful aid in the analysis of omics data. ALS is a severe and fatal neuromuscular disease, and the lack of truly effective treatment underlines the need to incorporate cutting-edge approaches to discover improved therapeutics. Currently in ALS research, vast amounts of omics and other experimental data are being generated. However, the application of MINs is minimal. This review has highlighted MIN approaches in tissues involved in ALS that could provide greater insight into the pathological processes at play in ALS. The application of these approaches not only to motor neurons but also to other cell types such as muscle and astrocytes, or to specific subcellular structures such as mitochondria, should be a priority to help refine our understanding of underlying cellular molecular mechanisms in ALS.</p>
<p>Asides from approaches using MINs, which have been the subject of this review, several studies have applied mathematical modelling to attempt to understand the pathology in terms of relationships between high-order disease concepts such as “genetic damage”, “necro-apoptosis”, “calcium homeostasis”, “cellular respiration”, and other processes [<xref ref-type="bibr" rid="B141-jpm-08-00044">141</xref>,<xref ref-type="bibr" rid="B142-jpm-08-00044">142</xref>], whereas others have mathematically modelled clinical features in order to better predict disease progression in each patient [<xref ref-type="bibr" rid="B143-jpm-08-00044">143</xref>,<xref ref-type="bibr" rid="B144-jpm-08-00044">144</xref>]. MIN approaches may ultimately feed into higher order and clinical models, for example if they are used to better define molecular pathways or molecular biomarkers.</p>
<p>At the molecular level, the increasing availability of high-throughput data from experimental models and from large-population genomic and functional genomic studies, together with the growth of molecular interaction datasets and the optimization of network-clustering algorithms, may provide an opportunity to take a fresh look at the mechanistic processes underlying cellular pathology in ALS. Molecular changes at the level of network modules could be described per individual, lending itself to personalized medicine machine-learning approaches to model the relationships between dysregulated pathways. The clarification of pathological processes involved in ALS will guide the identification of biomarkers and potential drug targets in the future.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank members of the NICSM neuromuscular team for stimulating discussion.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, W.D. and S.D.; writing—original draft preparation, S.M.; writing—review and editing, S.M., W.D., and S.D.; supervision, W.D. and S.D.</p>
</notes>
<notes>
<title>Funding</title>
<p>S.M. was supported by a studentship from the Department for Employment and Learning Northern Ireland. The research was also supported by the Target-ALS Foundation and the Northern Ireland Center for Stratified Medicine center grant (InvestNI).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflicts of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-jpm-08-00044">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logroscino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Hardiman</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Chiò</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Swingler</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Millul</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Benn</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Beghi</surname>
<given-names>E.</given-names>
</name>
<collab>EURALS</collab>
</person-group>
<article-title>Incidence of amyotrophic lateral sclerosis in Europe</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2010</year>
<volume>81</volume>
<fpage>385</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2009.183525</pub-id>
<pub-id pub-id-type="pmid">19710046</pub-id>
</element-citation>
</ref>
<ref id="B2-jpm-08-00044">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiò</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Logroscino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hardiman</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Swingler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Beghi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>B.G.</given-names>
</name>
<collab>Eurals Consortium</collab>
</person-group>
<article-title>Prognostic factors in ALS: A critical review</article-title>
<source/>Amyotroph. Lateral Scler.
          <year>2009</year>
<volume>10</volume>
<fpage>310</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="pmid">19922118</pub-id>
</element-citation>
</ref>
<ref id="B3-jpm-08-00044">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurland</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Mulder</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familial aggregations indicative of dominant inheritance. II</article-title>
<source/>Neurology
          <year>1955</year>
<volume>5</volume>
<fpage>249</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.5.4.249</pub-id>
<pub-id pub-id-type="pmid">14370376</pub-id>
</element-citation>
</ref>
<ref id="B4-jpm-08-00044">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byrne</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bede</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Elamin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kenna</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hardiman</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-analysis</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2011</year>
<volume>82</volume>
<fpage>623</fpage>
<lpage>627</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2010.224501</pub-id>
<pub-id pub-id-type="pmid">21047878</pub-id>
</element-citation>
</ref>
<ref id="B5-jpm-08-00044">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bettencourt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Exome sequencing uncovers hidden pathways in familial and sporadic ALS</article-title>
<source/>Nat. Neurosci.
          <year>2015</year>
<volume>18</volume>
<fpage>611</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4012</pub-id>
<pub-id pub-id-type="pmid">25919956</pub-id>
</element-citation>
</ref>
<ref id="B6-jpm-08-00044">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosen</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis</article-title>
<source/>Nature
          <year>1993</year>
<volume>364</volume>
<fpage>362</fpage>
<pub-id pub-id-type="doi">10.1038/364362c0</pub-id>
<pub-id pub-id-type="pmid">8332197</pub-id>
</element-citation>
</ref>
<ref id="B7-jpm-08-00044">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chiò</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications</article-title>
<source/>Lancet Neurol.
          <year>2018</year>
<volume>17</volume>
<fpage>94</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(17)30401-5</pub-id>
<pub-id pub-id-type="pmid">29154141</pub-id>
</element-citation>
</ref>
<ref id="B8-jpm-08-00044">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ticozzi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tiloca</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Colombrita</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Doretti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maderna</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Messina</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ratti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Silani</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Genetics of familial Amyotrophic lateral sclerosis</article-title>
<source/>Arch. Ital. Biol.
          <year>2011</year>
<volume>149</volume>
<fpage>65</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">21412717</pub-id>
</element-citation>
</ref>
<ref id="B9-jpm-08-00044">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renton</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Chiò</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>State of play in amyotrophic lateral sclerosis genetics</article-title>
<source/>Nat. Neurosci.
          <year>2014</year>
<volume>17</volume>
<fpage>17</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3584</pub-id>
<pub-id pub-id-type="pmid">24369373</pub-id>
</element-citation>
</ref>
<ref id="B10-jpm-08-00044">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pradat</surname>
<given-names>P.-F.</given-names>
</name>
<name>
<surname>Barani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wanschitz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dubourg</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lombès</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bigot</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mouly</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bruneteau</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Salachas</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lenglet</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormalities of satellite cells function in amyotrophic lateral sclerosis</article-title>
<source/>Amyotroph. Lateral Scler.
          <year>2011</year>
<volume>12</volume>
<fpage>264</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.3109/17482968.2011.566618</pub-id>
<pub-id pub-id-type="pmid">21473708</pub-id>
</element-citation>
</ref>
<ref id="B11-jpm-08-00044">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menzies</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Ince</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Mitochondrial involvement in amyotrophic lateral sclerosis</article-title>
<source/>Neurochem. Int.
          <year>2002</year>
<volume>40</volume>
<fpage>543</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1016/S0197-0186(01)00125-5</pub-id>
<pub-id pub-id-type="pmid">11850111</pub-id>
</element-citation>
</ref>
<ref id="B12-jpm-08-00044">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Heitzer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kanagaratnam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Goswami</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rizo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Troost</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients</article-title>
<source/>Glia
          <year>2015</year>
<volume>63</volume>
<fpage>2260</fpage>
<lpage>2273</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22891</pub-id>
<pub-id pub-id-type="pmid">26200799</pub-id>
</element-citation>
</ref>
<ref id="B13-jpm-08-00044">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brites</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vaz</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Microglia centered pathogenesis in ALS: Insights in cell interconnectivity</article-title>
<source/>Front. Cell. Neurosci.
          <year>2014</year>
<volume>8</volume>
<fpage>117</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00117</pub-id>
<pub-id pub-id-type="pmid">24904276</pub-id>
</element-citation>
</ref>
<ref id="B14-jpm-08-00044">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bensimon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lacomblez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meininger</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group</article-title>
<source/>N. Engl. J. Med.
          <year>1994</year>
<volume>330</volume>
<fpage>585</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199403033300901</pub-id>
<pub-id pub-id-type="pmid">8302340</pub-id>
</element-citation>
</ref>
<ref id="B15-jpm-08-00044">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lacomblez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bensimon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Leigh</surname>
<given-names>P.N.</given-names>
</name>
<name>
<surname>Guillet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Meininger</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II</article-title>
<source/>Lancet
          <year>1996</year>
<volume>347</volume>
<fpage>1425</fpage>
<lpage>1431</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(96)91680-3</pub-id>
<pub-id pub-id-type="pmid">8676624</pub-id>
</element-citation>
</ref>
<ref id="B16-jpm-08-00044">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)</article-title>
<source/>Cochrane Database Syst Rev.
          <year>2012</year>
<pub-id pub-id-type="doi">10.1002/14651858.CD001447.pub3</pub-id>
<pub-id pub-id-type="pmid">22419278</pub-id>
</element-citation>
</ref>
<ref id="B17-jpm-08-00044">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ginsberg</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cost effectiveness of treatments for amyotrophic lateral sclerosis: A review of the literature</article-title>
<source/>Pharmacoeconomics
          <year>2002</year>
<volume>20</volume>
<fpage>367</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="doi">10.2165/00019053-200220060-00002</pub-id>
<pub-id pub-id-type="pmid">12052096</pub-id>
</element-citation>
</ref>
<ref id="B18-jpm-08-00044">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Itoyama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sobue</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tsuji</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Doyu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hamada</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoneoka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Akimoto</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients</article-title>
<source/>Amyotroph. Lateral Scler. Frontotemporal Degener.
          <year>2014</year>
<volume>15</volume>
<fpage>610</fpage>
<lpage>617</lpage>
<pub-id pub-id-type="doi">10.3109/21678421.2014.959024</pub-id>
<pub-id pub-id-type="pmid">25286015</pub-id>
</element-citation>
</ref>
<ref id="B19-jpm-08-00044">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takei</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yuki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Akimoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sakata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Palumbo</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Edaravone and its clinical development for amyotrophic lateral sclerosis</article-title>
<source/>Amyotroph. Lateral Scler. Frontotemporal Degener.
          <year>2017</year>
<volume>18</volume>
<fpage>5</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1080/21678421.2017.1353101</pub-id>
<pub-id pub-id-type="pmid">28872907</pub-id>
</element-citation>
</ref>
<ref id="B20-jpm-08-00044">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshino</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)</article-title>
<source/>Amyotroph. Lateral Scler.
          <year>2006</year>
<volume>7</volume>
<fpage>241</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1080/17482960600881870</pub-id>
<pub-id pub-id-type="pmid">17127563</pub-id>
</element-citation>
</ref>
<ref id="B21-jpm-08-00044">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsuji</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Itoyama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sobue</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Togo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hamada</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akimoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial</article-title>
<source/>Lancet Neurol.
          <year>2017</year>
<volume>16</volume>
<fpage>505</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(17)30115-1</pub-id>
<pub-id pub-id-type="pmid">28522181</pub-id>
</element-citation>
</ref>
<ref id="B22-jpm-08-00044">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Randazzo</surname>
<given-names>W.T.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Beard</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis</article-title>
<source/>Neurology
          <year>2009</year>
<volume>72</volume>
<fpage>14</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000333251.36681.a5</pub-id>
<pub-id pub-id-type="pmid">18987350</pub-id>
</element-citation>
</ref>
<ref id="B23-jpm-08-00044">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganesalingam</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lacomis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bowser</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS</article-title>
<source/>J. Neurochem.
          <year>2011</year>
<volume>117</volume>
<fpage>528</fpage>
<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07224.x</pub-id>
<pub-id pub-id-type="pmid">21418221</pub-id>
</element-citation>
</ref>
<ref id="B24-jpm-08-00044">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakkar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boehringer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bowser</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Use of biomarkers in ALS drug development and clinical trials</article-title>
<source/>Brain Res.
          <year>2015</year>
<volume>1607</volume>
<fpage>94</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.10.031</pub-id>
<pub-id pub-id-type="pmid">25452025</pub-id>
</element-citation>
</ref>
<ref id="B25-jpm-08-00044">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boylan</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Crook</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Desaro</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Overstreet</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Polak</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis</article-title>
<source/>J. Neurol. Neurosurg. Psychiatry
          <year>2013</year>
<volume>84</volume>
<fpage>467</fpage>
<lpage>472</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2012-303768</pub-id>
<pub-id pub-id-type="pmid">23117489</pub-id>
</element-citation>
</ref>
<ref id="B26-jpm-08-00044">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keizman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rogowski</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Berliner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ish-Shalom</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maimon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nefussy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Artamonov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Drory</surname>
<given-names>V.E.</given-names>
</name>
</person-group>
<article-title>Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis</article-title>
<source/>Acta Neurol. Scand.
          <year>2009</year>
<volume>119</volume>
<fpage>383</fpage>
<lpage>389</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0404.2008.01112.x</pub-id>
<pub-id pub-id-type="pmid">18976328</pub-id>
</element-citation>
</ref>
<ref id="B27-jpm-08-00044">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>C.-S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.-T.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>M.D.-T.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>I.-L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H.-T.</given-names>
</name>
</person-group>
<article-title>Elevated serum autoantibody against high mobility group box 1 as a potent surrogate biomarker for amyotrophic lateral sclerosis</article-title>
<source/>Neurobiol. Dis.
          <year>2013</year>
<volume>58</volume>
<fpage>13</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.04.013</pub-id>
<pub-id pub-id-type="pmid">23639787</pub-id>
</element-citation>
</ref>
<ref id="B28-jpm-08-00044">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iłżecka</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Granzymes A and B levels in serum of patients with amyotrophic lateral sclerosis</article-title>
<source/>Clin. Biochem.
          <year>2011</year>
<volume>44</volume>
<fpage>650</fpage>
<lpage>653</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinbiochem.2011.02.006</pub-id>
<pub-id pub-id-type="pmid">21349256</pub-id>
</element-citation>
</ref>
<ref id="B29-jpm-08-00044">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Majounie</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Renton</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dopper</surname>
<given-names>E.G.P.</given-names>
</name>
<name>
<surname>Waite</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rollinson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chiò</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Restagno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nicolaou</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Simon-Sanchez</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study</article-title>
<source/>Lancet Neurol.
          <year>2012</year>
<volume>11</volume>
<fpage>323</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70043-1</pub-id>
<pub-id pub-id-type="pmid">22406228</pub-id>
</element-citation>
</ref>
<ref id="B30-jpm-08-00044">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byrne</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Elamin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bede</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shatunov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Corr</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Heverin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kenna</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study</article-title>
<source/>Lancet Neurol.
          <year>2012</year>
<volume>11</volume>
<fpage>232</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70014-5</pub-id>
<pub-id pub-id-type="pmid">22305801</pub-id>
</element-citation>
</ref>
<ref id="B31-jpm-08-00044">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasco</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vourc’h</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nadjar</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ribourtout</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Guettard</surname>
<given-names>Y.-O.</given-names>
</name>
<name>
<surname>Camu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Praline</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meininger</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>C.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis</article-title>
<source/>J. Neurol. Sci.
          <year>2011</year>
<volume>303</volume>
<fpage>124</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2010.12.018</pub-id>
<pub-id pub-id-type="pmid">21276595</pub-id>
</element-citation>
</ref>
<ref id="B32-jpm-08-00044">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diekstra</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>van Vught</surname>
<given-names>P.W.J.</given-names>
</name>
<name>
<surname>van Rheenen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Koppers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pasterkamp</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>van Es</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Schelhaas</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>de Visser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Robberecht</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Van Damme</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>UNC13A is a modifier of survival in amyotrophic lateral sclerosis</article-title>
<source/>Neurobiol. Aging.
          <year>2012</year>
<volume>33</volume>
<fpage>630. e3</fpage>
<lpage>630. e8</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.10.029</pub-id>
</element-citation>
</ref>
<ref id="B33-jpm-08-00044">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tetsuka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Uehara</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ikegawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>ZNF512B gene is a prognostic factor in patients with amyotrophic lateral sclerosis</article-title>
<source/>J. Neurol. Sci.
          <year>2013</year>
<volume>324</volume>
<fpage>163</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2012.10.029</pub-id>
<pub-id pub-id-type="pmid">23168171</pub-id>
</element-citation>
</ref>
<ref id="B34-jpm-08-00044">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Woodhouse</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kirkcaldie</surname>
<given-names>M.T.K.</given-names>
</name>
<name>
<surname>Vickers</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Excitotoxicity in ALS: Overstimulation, or overreaction?</article-title>
<source/>Exp. Neurol.
          <year>2016</year>
<volume>275 Pt 1</volume>
<fpage>162</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2015.09.019</pub-id>
<pub-id pub-id-type="pmid">26584004</pub-id>
</element-citation>
</ref>
<ref id="B35-jpm-08-00044">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allaman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bélanger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Magistretti</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Astrocyte-neuron metabolic relationships: For better and for worse</article-title>
<source/>Trends Neurosci.
          <year>2011</year>
<volume>34</volume>
<fpage>76</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2010.12.001</pub-id>
<pub-id pub-id-type="pmid">21236501</pub-id>
</element-citation>
</ref>
<ref id="B36-jpm-08-00044">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>H.Z.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Marked synergism between mutant SOD1 and glutamate transport inhibition in the induction of motor neuronal degeneration in spinal cord slice cultures</article-title>
<source/>Brain Res.
          <year>2012</year>
<volume>1448</volume>
<fpage>153</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2012.02.005</pub-id>
<pub-id pub-id-type="pmid">22370146</pub-id>
</element-citation>
</ref>
<ref id="B37-jpm-08-00044">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nosyreva</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kavalali</surname>
<given-names>E.T.</given-names>
</name>
</person-group>
<article-title>Activity-dependent augmentation of spontaneous neurotransmission during endoplasmic reticulum stress</article-title>
<source/>J. Neurosci.
          <year>2010</year>
<volume>30</volume>
<fpage>7358</fpage>
<lpage>7368</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5358-09.2010</pub-id>
<pub-id pub-id-type="pmid">20505103</pub-id>
</element-citation>
</ref>
<ref id="B38-jpm-08-00044">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muyderman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in amyotrophic lateral sclerosis—A valid pharmacological target?</article-title>
<source/>Br. J. Pharmacol.
          <year>2014</year>
<volume>171</volume>
<fpage>2191</fpage>
<lpage>2205</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12476</pub-id>
<pub-id pub-id-type="pmid">24148000</pub-id>
</element-citation>
</ref>
<ref id="B39-jpm-08-00044">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pickles</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Destroismaisons</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Peyrard</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Cadot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rouleau</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Julien</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Arbour</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vande Velde</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1</article-title>
<source/>Hum. Mol. Genet.
          <year>2013</year>
<volume>22</volume>
<fpage>3947</fpage>
<lpage>3959</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt249</pub-id>
<pub-id pub-id-type="pmid">23736301</pub-id>
</element-citation>
</ref>
<ref id="B40-jpm-08-00044">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis</article-title>
<source/>Acta Neuropathol.
          <year>2007</year>
<volume>114</volume>
<fpage>633</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-007-0299-1</pub-id>
<pub-id pub-id-type="pmid">17929040</pub-id>
</element-citation>
</ref>
<ref id="B41-jpm-08-00044">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harraz</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Marden</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sharov</surname>
<given-names>V.S.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schöneich</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model</article-title>
<source/>J. Clin. Investig.
          <year>2008</year>
<volume>118</volume>
<fpage>659</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="doi">10.1172/JCI34060</pub-id>
<pub-id pub-id-type="pmid">18219391</pub-id>
</element-citation>
</ref>
<ref id="B42-jpm-08-00044">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackenzie</surname>
<given-names>I.R.A.</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Ince</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Geser</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Forman</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Ravits</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations</article-title>
<source/>Ann. Neurol.
          <year>2007</year>
<volume>61</volume>
<fpage>427</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21147</pub-id>
<pub-id pub-id-type="pmid">17469116</pub-id>
</element-citation>
</ref>
<ref id="B43-jpm-08-00044">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>C.-F.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tanji</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kakita</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>TDP-43-immunoreactive neuronal and glial inclusions in the neostriatum in amyotrophic lateral sclerosis with and without dementia</article-title>
<source/>Acta Neuropathol.
          <year>2008</year>
<volume>115</volume>
<fpage>115</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-007-0285-7</pub-id>
<pub-id pub-id-type="pmid">17786458</pub-id>
</element-citation>
</ref>
<ref id="B44-jpm-08-00044">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwiatkowski</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Bosco</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Leclerc</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Tamrazian</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vanderburg</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Russ</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gilchrist</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kasarskis</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Munsat</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis</article-title>
<source/>Science
          <year>2009</year>
<volume>323</volume>
<fpage>1205</fpage>
<lpage>1208</lpage>
<pub-id pub-id-type="doi">10.1126/science.1166066</pub-id>
<pub-id pub-id-type="pmid">19251627</pub-id>
</element-citation>
</ref>
<ref id="B45-jpm-08-00044">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hortobágyi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Troakes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Seelaar</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Al-Sarraj</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rogelj</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C.E.</given-names>
</name>
</person-group>
<article-title>Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders</article-title>
<source/>Acta Neuropathol.
          <year>2011</year>
<volume>121</volume>
<fpage>519</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-011-0813-3</pub-id>
<pub-id pub-id-type="pmid">21360076</pub-id>
</element-citation>
</ref>
<ref id="B46-jpm-08-00044">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Warraich</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Solski</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Fernando</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rouleau</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>I.P.</given-names>
</name>
</person-group>
<article-title>UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis</article-title>
<source/>Neurobiol. Aging
          <year>2012</year>
<volume>33</volume>
<fpage>2527. e3</fpage>
<lpage>2527. e10</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.05.008</pub-id>
</element-citation>
</ref>
<ref id="B47-jpm-08-00044">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Topol</surname>
<given-names>EJ.</given-names>
</name>
</person-group>
<article-title>Individualized medicine from prewomb to tomb</article-title>
<source/>Cell.
          <year>2014</year>
<volume>157</volume>
<fpage>241</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2014.02.012</pub-id>
<pub-id pub-id-type="pmid">24679539</pub-id>
</element-citation>
</ref>
<ref id="B48-jpm-08-00044">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>U.A.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics—Five decades of therapeutic lessons from genetic diversity</article-title>
<source/>Nat. Rev. Genet.
          <year>2004</year>
<volume>5</volume>
<fpage>669</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="doi">10.1038/nrg1428</pub-id>
<pub-id pub-id-type="pmid">15372089</pub-id>
</element-citation>
</ref>
<ref id="B49-jpm-08-00044">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riordan</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Rommens</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kerem</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Alon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rozmahel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grzelczak</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zielenski</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lok</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Plavsic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA</article-title>
<source/>Science
          <year>1989</year>
<volume>245</volume>
<fpage>1066</fpage>
<lpage>1073</lpage>
<pub-id pub-id-type="doi">10.1126/science.2475911</pub-id>
<pub-id pub-id-type="pmid">2475911</pub-id>
</element-citation>
</ref>
<ref id="B50-jpm-08-00044">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rommens</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Iannuzzi</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Kerem</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Drumm</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Melmer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rozmahel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hidaka</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Identification of the cystic fibrosis gene: Chromosome walking and jumping</article-title>
<source/>Science
          <year>1989</year>
<volume>245</volume>
<fpage>1059</fpage>
<lpage>1065</lpage>
<pub-id pub-id-type="doi">10.1126/science.2772657</pub-id>
<pub-id pub-id-type="pmid">2772657</pub-id>
</element-citation>
</ref>
<ref id="B51-jpm-08-00044">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerem</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rommens</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Markiewicz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Chakravarti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Buchwald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsui</surname>
<given-names>L.C.</given-names>
</name>
</person-group>
<article-title>Identification of the cystic fibrosis gene: Genetic analysis</article-title>
<source/>Science
          <year>1989</year>
<volume>245</volume>
<fpage>1073</fpage>
<lpage>1080</lpage>
<pub-id pub-id-type="doi">10.1126/science.2570460</pub-id>
<pub-id pub-id-type="pmid">2570460</pub-id>
</element-citation>
</ref>
<ref id="B52-jpm-08-00044">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowe</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sorscher</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Cystic fibrosis</article-title>
<source/>N. Engl. J. Med.
          <year>2005</year>
<volume>352</volume>
<fpage>1992</fpage>
<lpage>2001</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra043184</pub-id>
<pub-id pub-id-type="pmid">15888700</pub-id>
</element-citation>
</ref>
<ref id="B53-jpm-08-00044">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Accurso</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Clancy</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Dunitz</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Durie</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Sagel</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Hornick</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Konstan</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Donaldson</surname>
<given-names>S.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation</article-title>
<source/>N. Engl. J. Med.
          <year>2010</year>
<volume>363</volume>
<fpage>1991</fpage>
<lpage>2003</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa0909825</pub-id>
<pub-id pub-id-type="pmid">21083385</pub-id>
</element-citation>
</ref>
<ref id="B54-jpm-08-00044">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wainwright</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Elborn</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Ramsey</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Marigowda</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cipolli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>De Boeck</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Flume</surname>
<given-names>P.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR</article-title>
<source/>N. Engl. J. Med.
          <year>2015</year>
<volume>373</volume>
<fpage>220</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1409547</pub-id>
<pub-id pub-id-type="pmid">25981758</pub-id>
</element-citation>
</ref>
<ref id="B55-jpm-08-00044">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donaldson</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Pilewski</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Griese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cooke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Viswanathan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tullis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Lekstrom-Himes</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.T.</given-names>
</name>
<collab>VX11-661-101 Study Group</collab>
</person-group>
<article-title>Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>2018</year>
<volume>197</volume>
<fpage>214</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201704-0717OC</pub-id>
<pub-id pub-id-type="pmid">28930490</pub-id>
</element-citation>
</ref>
<ref id="B56-jpm-08-00044">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sala</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Tezacaftor for the treatment of cystic fibrosis</article-title>
<source/>Expert Rev. Respir. Med.
          <year>2018</year>
<volume>12</volume>
<fpage>725</fpage>
<lpage>732</lpage>
<pub-id pub-id-type="doi">10.1080/17476348.2018.1507741</pub-id>
<pub-id pub-id-type="pmid">30073878</pub-id>
</element-citation>
</ref>
<ref id="B57-jpm-08-00044">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramsey</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McElvaney</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Tullis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Dřevínek</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Griese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McKone</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Wainwright</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Konstan</surname>
<given-names>M.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A CFTR Potentiator in Patients with Cystic Fibrosis and the <italic>G551D</italic> Mutation</article-title>
<source/>N. Engl. J. Med.
          <year>2011</year>
<volume>365</volume>
<fpage>1663</fpage>
<lpage>1672</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1105185</pub-id>
<pub-id pub-id-type="pmid">22047557</pub-id>
</element-citation>
</ref>
<ref id="B58-jpm-08-00044">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawicki</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>McKone</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Pasta</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Wagener</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Konstan</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data</article-title>
<source/>Am. J. Respir. Crit. Care Med.
          <year>2015</year>
<volume>192</volume>
<fpage>836</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201503-0578OC</pub-id>
<pub-id pub-id-type="pmid">26132840</pub-id>
</element-citation>
</ref>
<ref id="B59-jpm-08-00044">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konstan</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>McKone</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Marigowda</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Waltz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lubarsky</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>S.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): A phase 3, extension study</article-title>
<source/>Lancet Respir. Med.
          <year>2017</year>
<volume>5</volume>
<fpage>107</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1016/S2213-2600(16)30427-1</pub-id>
<pub-id pub-id-type="pmid">28011037</pub-id>
</element-citation>
</ref>
<ref id="B60-jpm-08-00044">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>D.-Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.-A.</given-names>
</name>
<name>
<surname>Przytycka</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>Chapter 5: Network biology approach to complex diseases</article-title>
<source/>PLoS Comput. Biol.
          <year>2012</year>
<volume>8</volume>
<elocation-id>e1002820</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1002820</pub-id>
<pub-id pub-id-type="pmid">23300411</pub-id>
</element-citation>
</ref>
<ref id="B61-jpm-08-00044">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barabási</surname>
<given-names>A.-L.</given-names>
</name>
</person-group>
<article-title>Scale-free networks: A decade and beyond</article-title>
<source/>Science
          <year>2009</year>
<volume>325</volume>
<fpage>412</fpage>
<lpage>413</lpage>
<pub-id pub-id-type="doi">10.1126/science.1173299</pub-id>
<pub-id pub-id-type="pmid">19628854</pub-id>
</element-citation>
</ref>
<ref id="B62-jpm-08-00044">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ideker</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sharan</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Protein networks in disease</article-title>
<source/>Genome Res.
          <year>2008</year>
<volume>18</volume>
<fpage>644</fpage>
<lpage>652</lpage>
<pub-id pub-id-type="doi">10.1101/gr.071852.107</pub-id>
<pub-id pub-id-type="pmid">18381899</pub-id>
</element-citation>
</ref>
<ref id="B63-jpm-08-00044">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rayner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Protein-protein interaction reveals synergistic discrimination of cancer phenotype</article-title>
<source/>Cancer Inform.
          <year>2010</year>
<volume>9</volume>
<fpage>61</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.4137/CIN.S3899</pub-id>
<pub-id pub-id-type="pmid">20458363</pub-id>
</element-citation>
</ref>
<ref id="B64-jpm-08-00044">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Southworth</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Aging mice show a decreasing correlation of gene expression within genetic modules</article-title>
<source/>PLoS Genet.
          <year>2009</year>
<volume>5</volume>
<elocation-id>e1000776</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1000776</pub-id>
<pub-id pub-id-type="pmid">20019809</pub-id>
</element-citation>
</ref>
<ref id="B65-jpm-08-00044">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barabási</surname>
<given-names>A.-L.</given-names>
</name>
<name>
<surname>Gulbahce</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Loscalzo</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Network medicine: A network-based approach to human disease</article-title>
<source/>Nat Rev Genet.
          <year>2011</year>
<volume>12</volume>
<fpage>56</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2918</pub-id>
<pub-id pub-id-type="pmid">21164525</pub-id>
</element-citation>
</ref>
<ref id="B66-jpm-08-00044">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csermely</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Agoston</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pongor</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The efficiency of multi-target drugs: The network approach might help drug design</article-title>
<source/>Trends Pharmacol.Sci.
          <year>2005</year>
<volume>26</volume>
<fpage>178</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2005.02.007</pub-id>
<pub-id pub-id-type="pmid">15808341</pub-id>
</element-citation>
</ref>
<ref id="B67-jpm-08-00044">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wilhite</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Ledoux</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.F.</given-names>
</name>
<name>
<surname>Tomashevsky</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Phillippy</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Holko</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NCBI GEO: Archive for functional genomics data sets—Update</article-title>
<source/>Nucleic Acids Res.
          <year>2013</year>
<volume>41</volume>
<fpage>D991</fpage>
<lpage>D995</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gks1193</pub-id>
<pub-id pub-id-type="pmid">23193258</pub-id>
</element-citation>
</ref>
<ref id="B68-jpm-08-00044">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parkinson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sarkans</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kolesnikov</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Abeygunawardena</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Burdett</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dylag</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Emam</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Farne</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hastings</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Holloway</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ArrayExpress update—An archive of microarray and high-throughput sequencing-based functional genomics experiments</article-title>
<source/>Nucleic Acids Res.
          <year>2011</year>
<volume>39</volume>
<fpage>D1002</fpage>
<lpage>D1004</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkq1040</pub-id>
<pub-id pub-id-type="pmid">21071405</pub-id>
</element-citation>
</ref>
<ref id="B69-jpm-08-00044">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conlon</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Fagegaltier</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Agius</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Davis-Porada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<collab>New York Genome Center ALS Consortium</collab>
<name>
<surname>Phatnani</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism</article-title>
<source/>Elife
          <year>2018</year>
<volume>7</volume>
<fpage>e37754</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.37754</pub-id>
<pub-id pub-id-type="pmid">30003873</pub-id>
</element-citation>
</ref>
<ref id="B70-jpm-08-00044">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langfelder</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>WGCNA: An R package for weighted correlation network analysis</article-title>
<source/>BMC Bioinform.
          <year>2008</year>
<volume>9</volume>
<elocation-id>559</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id>
</element-citation>
</ref>
<ref id="B71-jpm-08-00044">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuart</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Koller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>A gene-coexpression network for global discovery of conserved genetic modules</article-title>
<source/>Science
          <year>2003</year>
<volume>302</volume>
<fpage>249</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1126/science.1087447</pub-id>
<pub-id pub-id-type="pmid">12934013</pub-id>
</element-citation>
</ref>
<ref id="B72-jpm-08-00044">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saris</surname>
<given-names>C.G.J.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Vught</surname>
<given-names>P.W.J.</given-names>
</name>
<name>
<surname>van Es</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Blauw</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Langfelder</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>DeYoung</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wokke</surname>
<given-names>J.H.J.</given-names>
</name>
<name>
<surname>Veldink</surname>
<given-names>J.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients</article-title>
<source/>BMC Genom.
          <year>2009</year>
<volume>10</volume>
<elocation-id>405</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2164-10-405</pub-id>
<pub-id pub-id-type="pmid">19712483</pub-id>
</element-citation>
</ref>
<ref id="B73-jpm-08-00044">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtman</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Raj</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Schaafsma</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Brouwer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wes</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Möller</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Orre</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kamphuis</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: A co-expression meta-analysis</article-title>
<source/>Acta Neuropathol. Commun.
          <year>2015</year>
<volume>3</volume>
<fpage>31</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-015-0203-5</pub-id>
<pub-id pub-id-type="pmid">26001565</pub-id>
</element-citation>
</ref>
<ref id="B74-jpm-08-00044">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prudencio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Belzil</surname>
<given-names>V.V.</given-names>
</name>
<name>
<surname>Batra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Gendron</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Pregent</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Overstreet</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Piazza-Johnston</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Desaro</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS</article-title>
<source/>Nat. Neurosci.
          <year>2015</year>
<volume>18</volume>
<fpage>1175</fpage>
<lpage>1182</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4065</pub-id>
<pub-id pub-id-type="pmid">26192745</pub-id>
</element-citation>
</ref>
<ref id="B75-jpm-08-00044">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper-Knock</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bury</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Wyles</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Higginbottom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gelsthorpe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Highley</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Hautbergue</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rattray</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>C9ORF72 GGGGCC expanded repeats produce splicing dysregulation which correlates with disease severity in amyotrophic lateral sclerosis</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0127376</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0127376</pub-id>
<pub-id pub-id-type="pmid">26016851</pub-id>
</element-citation>
</ref>
<ref id="B76-jpm-08-00044">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukund</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Subramaniam</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Co-expression Network Approach Reveals Functional Similarities among Diseases Affecting Human Skeletal Muscle</article-title>
<source/>Front Physiol
          <year>2017</year>
<volume>8</volume>
<fpage>980</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2017.00980</pub-id>
<pub-id pub-id-type="pmid">29249983</pub-id>
</element-citation>
</ref>
<ref id="B77-jpm-08-00044">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotni</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>D.-Q.</given-names>
</name>
</person-group>
<article-title>Gene expression profiles and protein-protein interaction networks in amyotrophic lateral sclerosis patients with C9orf72 mutation</article-title>
<source/>Orphanet J. Rare Dis.
          <year>2016</year>
<volume>11</volume>
<fpage>148</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-016-0531-y</pub-id>
<pub-id pub-id-type="pmid">27814735</pub-id>
</element-citation>
</ref>
<ref id="B78-jpm-08-00044">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brohawn</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>RNAseq Analyses Identify Tumor Necrosis Factor-Mediated Inflammation as a Major Abnormality in ALS Spinal Cord</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0160520</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0160520</pub-id>
<pub-id pub-id-type="pmid">27487029</pub-id>
</element-citation>
</ref>
<ref id="B79-jpm-08-00044">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welter</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>MacArthur</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Burdett</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Junkins</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Klemm</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Flicek</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Manolio</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hindorff</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The NHGRI GWAS Catalog, a curated resource of SNP-trait associations</article-title>
<source/>Nucleic Acids Res.
          <year>2014</year>
<volume>42</volume>
<fpage>D1001</fpage>
<lpage>D1006</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkt1229</pub-id>
<pub-id pub-id-type="pmid">24316577</pub-id>
</element-citation>
</ref>
<ref id="B80-jpm-08-00044">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abel</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Al-Chalabi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics</article-title>
<source/>Hum. Mutat.
          <year>2012</year>
<volume>33</volume>
<fpage>1345</fpage>
<lpage>1351</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22157</pub-id>
<pub-id pub-id-type="pmid">22753137</pub-id>
</element-citation>
</ref>
<ref id="B81-jpm-08-00044">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kenna</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Renton</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Ticozzi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Faghri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dominov</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Kenna</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Nalls</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Keagle</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide Analyses Identify KIF5A as a Novel ALS Gene</article-title>
<source/>Neuron
          <year>2018</year>
<volume>97</volume>
<fpage>1268</fpage>
<lpage>1283</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2018.02.027</pub-id>
<pub-id pub-id-type="pmid">29566793</pub-id>
</element-citation>
</ref>
<ref id="B82-jpm-08-00044">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Genome-wide association study combining pathway analysis for typical sporadic amyotrophic lateral sclerosis in Chinese Han populations</article-title>
<source/>Neurobiol. Aging
          <year>2014</year>
<volume>35</volume>
<fpage>1778. e9</fpage>
<lpage>1778. e23</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.01.014</pub-id>
</element-citation>
</ref>
<ref id="B83-jpm-08-00044">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landers</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Melki</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meininger</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>van den Berg</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>van Es</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Sapp</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>van Vught</surname>
<given-names>P.W.J.</given-names>
</name>
<name>
<surname>McKenna-Yasek</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Blauw</surname>
<given-names>H.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>9004</fpage>
<lpage>9009</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0812937106</pub-id>
<pub-id pub-id-type="pmid">19451621</pub-id>
</element-citation>
</ref>
<ref id="B84-jpm-08-00044">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reisinger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Del-Toro</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ternent</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hermjakob</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Vizcaíno</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Introducing the PRIDE Archive RESTful web services</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>W599</fpage>
<lpage>W604</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkv382</pub-id>
<pub-id pub-id-type="pmid">25904633</pub-id>
</element-citation>
</ref>
<ref id="B85-jpm-08-00044">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tank</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Figueroa-Romero</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hinder</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Bedi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Archbold</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Weskamp</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Safren</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Paez-Colasante</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pacut</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal RNA stability in amyotrophic lateral sclerosis</article-title>
<source/>Nat. Commun.
          <year>2018</year>
<volume>9</volume>
<fpage>2845</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-05049-z</pub-id>
<pub-id pub-id-type="pmid">30030424</pub-id>
</element-citation>
</ref>
<ref id="B86-jpm-08-00044">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iradi</surname>
<given-names>M.C.G.</given-names>
</name>
<name>
<surname>Triplett</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Davila</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Crown</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rodriguez-Lebron</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>4049</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-21371-4</pub-id>
<pub-id pub-id-type="pmid">29511296</pub-id>
</element-citation>
</ref>
<ref id="B87-jpm-08-00044">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendonça</surname>
<given-names>D.M.F.</given-names>
</name>
<name>
<surname>Pizzati</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mostacada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>de SMartins</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Higashi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ayres Sá</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moura Neto</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Chimelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.M.B.</given-names>
</name>
</person-group>
<article-title>Neuroproteomics: An insight into ALS</article-title>
<source/>Neurol. Res.
          <year>2012</year>
<volume>34</volume>
<fpage>937</fpage>
<lpage>943</lpage>
<pub-id pub-id-type="doi">10.1179/1743132812Y.0000000092</pub-id>
<pub-id pub-id-type="pmid">23146297</pub-id>
</element-citation>
</ref>
<ref id="B88-jpm-08-00044">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasinetti</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Ungar</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Yemul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Cudkowicz</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Newhall</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Peskind</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of potential CSF biomarkers in ALS</article-title>
<source/>Neurology
          <year>2006</year>
<volume>66</volume>
<fpage>1218</fpage>
<lpage>1222</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000203129.82104.07</pub-id>
<pub-id pub-id-type="pmid">16481598</pub-id>
</element-citation>
</ref>
<ref id="B89-jpm-08-00044">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szklarczyk</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wyder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Simonovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Doncheva</surname>
<given-names>N.T.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bork</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible</article-title>
<source/>Nucleic Acids Res.
          <year>2017</year>
<volume>45</volume>
<fpage>D362</fpage>
<lpage>D368</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw937</pub-id>
<pub-id pub-id-type="pmid">27924014</pub-id>
</element-citation>
</ref>
<ref id="B90-jpm-08-00044">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatr-Aryamontri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Breitkreutz</surname>
<given-names>B.-J.</given-names>
</name>
<name>
<surname>Oughtred</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Boucher</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Heinicke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stark</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Breitkreutz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kolas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The BioGRID interaction database: 2015 update</article-title>
<source/>Nucleic Acids Res.
          <year>2015</year>
<volume>43</volume>
<fpage>D470</fpage>
<lpage>D478</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gku1204</pub-id>
<pub-id pub-id-type="pmid">25428363</pub-id>
</element-citation>
</ref>
<ref id="B91-jpm-08-00044">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerrien</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aranda</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Breuza</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bridge</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Broackes-Carter</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duesbury</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dumousseau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Feuermann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hinz</surname>
<given-names>U.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The IntAct molecular interaction database in 2012</article-title>
<source/>Nucleic Acids Res.
          <year>2012</year>
<volume>40</volume>
<fpage>D841</fpage>
<lpage>D846</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkr1088</pub-id>
<pub-id pub-id-type="pmid">22121220</pub-id>
</element-citation>
</ref>
<ref id="B92-jpm-08-00044">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wishart</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Jewison</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Knox</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Djoumbou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aziat</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HMDB 3.0—The Human Metabolome Database in 2013</article-title>
<source/>Nucleic Acids Res.
          <year>2013</year>
<volume>41</volume>
<fpage>D801</fpage>
<lpage>D807</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gks1065</pub-id>
<pub-id pub-id-type="pmid">23161693</pub-id>
</element-citation>
</ref>
<ref id="B93-jpm-08-00044">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bötzel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vogeser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lorenzl</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Elevated levels of methylmalonate and homocysteine in Parkinson’s disease, progressive supranuclear palsy and amyotrophic lateral sclerosis</article-title>
<source/>Dement. Geriatr. Cogn. Disord.
          <year>2010</year>
<volume>29</volume>
<fpage>553</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.1159/000314841</pub-id>
<pub-id pub-id-type="pmid">20606437</pub-id>
</element-citation>
</ref>
<ref id="B94-jpm-08-00044">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malin</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Ködding</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fuhrmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>von zur Mühlen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>T4, T3 and rT3 levels in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis</article-title>
<source/>J. Neurol.
          <year>1989</year>
<volume>236</volume>
<fpage>57</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1007/BF00314221</pub-id>
<pub-id pub-id-type="pmid">2915230</pub-id>
</element-citation>
</ref>
<ref id="B95-jpm-08-00044">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hozumi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koumura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patterns of levels of biological metals in CSF differ among neurodegenerative diseases</article-title>
<source/>J. Neurol. Sci.
          <year>2011</year>
<volume>303</volume>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2011.01.003</pub-id>
<pub-id pub-id-type="pmid">21292280</pub-id>
</element-citation>
</ref>
<ref id="B96-jpm-08-00044">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boll</surname>
<given-names>M.-C.</given-names>
</name>
<name>
<surname>Alcaraz-Zubeldia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montes</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murillo-Bonilla</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rios</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients</article-title>
<source/>Neurochem. Res.
          <year>2003</year>
<volume>28</volume>
<fpage>699</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1023/A:1022853531855</pub-id>
<pub-id pub-id-type="pmid">12716019</pub-id>
</element-citation>
</ref>
<ref id="B97-jpm-08-00044">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Stankovic</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Meininger</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Coggan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brew</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Guillemin</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>The kynurenine pathway and inflammation in amyotrophic lateral sclerosis</article-title>
<source/>Neurotox Res.
          <year>2010</year>
<volume>18</volume>
<fpage>132</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-009-9129-7</pub-id>
<pub-id pub-id-type="pmid">19921535</pub-id>
</element-citation>
</ref>
<ref id="B98-jpm-08-00044">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Teismann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stevic</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Halaschek-Wiener</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deecke</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kostic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Przedborski</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients</article-title>
<source/>Neurology
          <year>2002</year>
<volume>58</volume>
<fpage>1277</fpage>
<lpage>1279</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.58.8.1277</pub-id>
<pub-id pub-id-type="pmid">11971099</pub-id>
</element-citation>
</ref>
<ref id="B99-jpm-08-00044">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruijn</surname>
<given-names>L.I.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Unraveling the mechanisms involved in motor neuron degeneration in ALS</article-title>
<source/>Annu. Rev. Neurosci.
          <year>2004</year>
<volume>27</volume>
<fpage>723</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.27.070203.144244</pub-id>
<pub-id pub-id-type="pmid">15217349</pub-id>
</element-citation>
</ref>
<ref id="B100-jpm-08-00044">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boillée</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vande Velde</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>ALS: A disease of motor neurons and their nonneuronal neighbors</article-title>
<source/>Neuron
          <year>2006</year>
<volume>52</volume>
<fpage>39</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.018</pub-id>
<pub-id pub-id-type="pmid">17015226</pub-id>
</element-citation>
</ref>
<ref id="B101-jpm-08-00044">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dadon-Nachum</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Melamed</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Offen</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The “dying-back” phenomenon of motor neurons in ALS</article-title>
<source/>J. Mol. Neurosci.
          <year>2011</year>
<volume>43</volume>
<fpage>470</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-010-9467-1</pub-id>
<pub-id pub-id-type="pmid">21057983</pub-id>
</element-citation>
</ref>
<ref id="B102-jpm-08-00044">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sances</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gowing</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Amoroso</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>O’Rourke</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Sahabian</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wichterle</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baloh</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Sareen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Svendsen</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>ALS disrupts spinal motor neuron maturation and aging pathways within gene co-expression networks</article-title>
<source/>Nat. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>1256</fpage>
<lpage>1267</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4345</pub-id>
<pub-id pub-id-type="pmid">27428653</pub-id>
</element-citation>
</ref>
<ref id="B103-jpm-08-00044">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matus</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Valenzuela</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Medinas</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Hetz</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>ER Dysfunction and Protein Folding Stress in ALS</article-title>
<source/>Int. J. Cell Biol.
          <year>2013</year>
<volume>2013</volume>
<fpage>674751</fpage>
<pub-id pub-id-type="doi">10.1155/2013/674751</pub-id>
<pub-id pub-id-type="pmid">24324498</pub-id>
</element-citation>
</ref>
<ref id="B104-jpm-08-00044">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruijn</surname>
<given-names>L.I.</given-names>
</name>
<name>
<surname>Houseweart</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Ohama</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Reaume</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1</article-title>
<source/>Science
          <year>1998</year>
<volume>281</volume>
<fpage>1851</fpage>
<lpage>1854</lpage>
<pub-id pub-id-type="doi">10.1126/science.281.5384.1851</pub-id>
<pub-id pub-id-type="pmid">9743498</pub-id>
</element-citation>
</ref>
<ref id="B105-jpm-08-00044">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cloyd</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Rothstein</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Rajendran</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Aggregate formation in Cu,Zn superoxide dismutase-related proteins</article-title>
<source/>J. Biol. Chem.
          <year>2003</year>
<volume>278</volume>
<fpage>14331</fpage>
<lpage>14336</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M211698200</pub-id>
<pub-id pub-id-type="pmid">12551935</pub-id>
</element-citation>
</ref>
<ref id="B106-jpm-08-00044">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dykes-Hoberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Culotta</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Rothstein</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues</article-title>
<source/>Neurobiol. Dis.
          <year>2001</year>
<volume>8</volume>
<fpage>933</fpage>
<lpage>941</lpage>
<pub-id pub-id-type="doi">10.1006/nbdi.2001.0443</pub-id>
<pub-id pub-id-type="pmid">11741389</pub-id>
</element-citation>
</ref>
<ref id="B107-jpm-08-00044">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Deerlin</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Leverenz</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Bekris</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Elman</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Clay</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Chen-Plotkin</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Martinez-Lage</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis</article-title>
<source/>Lancet Neurol.
          <year>2008</year>
<volume>7</volume>
<fpage>409</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(08)70071-1</pub-id>
<pub-id pub-id-type="pmid">18396105</pub-id>
</element-citation>
</ref>
<ref id="B108-jpm-08-00044">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corrado</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ratti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gellera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Buratti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Castellotti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Carlomagno</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ticozzi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mazzini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Taroni</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis</article-title>
<source/>Hum. Mutat.
          <year>2009</year>
<volume>30</volume>
<fpage>688</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1002/humu.20950</pub-id>
<pub-id pub-id-type="pmid">19224587</pub-id>
</element-citation>
</ref>
<ref id="B109-jpm-08-00044">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kabashi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Valdmanis</surname>
<given-names>P.N.</given-names>
</name>
<name>
<surname>Dion</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Spiegelman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>McConkey</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Vande Velde</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bouchard</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Lacomblez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pochigaeva</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Salachas</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis</article-title>
<source/>Nat. Genet.
          <year>2008</year>
<volume>40</volume>
<fpage>572</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.1038/ng.132</pub-id>
<pub-id pub-id-type="pmid">18372902</pub-id>
</element-citation>
</ref>
<ref id="B110-jpm-08-00044">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiang</surname>
<given-names>H.-H.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Tysnes</surname>
<given-names>O.-B.</given-names>
</name>
<name>
<surname>Gredal</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>P.B.</given-names>
</name>
<name>
<surname>Graff</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Novel TARDBP mutations in Nordic ALS patients</article-title>
<source/>J. Hum. Genet.
          <year>2012</year>
<volume>57</volume>
<fpage>316</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1038/jhg.2012.24</pub-id>
<pub-id pub-id-type="pmid">22456481</pub-id>
</element-citation>
</ref>
<ref id="B111-jpm-08-00044">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raj</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shulman</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Keenan</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Chibnik</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Stranger</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>De Jager</surname>
<given-names>P.L.</given-names>
</name>
</person-group>
<article-title>Alzheimer disease susceptibility loci: Evidence for a protein network under natural selection</article-title>
<source/>Am. J. Hum. Genet.
          <year>2012</year>
<volume>90</volume>
<fpage>720</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2012.02.022</pub-id>
<pub-id pub-id-type="pmid">22482808</pub-id>
</element-citation>
</ref>
<ref id="B112-jpm-08-00044">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karakoc</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Krumm</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<fpage>246</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1038/nature10989</pub-id>
<pub-id pub-id-type="pmid">22495309</pub-id>
</element-citation>
</ref>
<ref id="B113-jpm-08-00044">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Neuronal intermediate filaments and ALS: A new look at an old question</article-title>
<source/>Biochim. Biophys. Acta Mol. Basis Dis.
          <year>2006</year>
<volume>1762</volume>
<fpage>1001</fpage>
<lpage>1012</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2006.09.003</pub-id>
<pub-id pub-id-type="pmid">17045786</pub-id>
</element-citation>
</ref>
<ref id="B114-jpm-08-00044">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szaro</surname>
<given-names>B.G.</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Post-transcriptional control of neurofilaments: New roles in development, regeneration and neurodegenerative disease</article-title>
<source/>Trends Neurosci.
          <year>2010</year>
<volume>33</volume>
<fpage>27</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2009.10.002</pub-id>
<pub-id pub-id-type="pmid">19906448</pub-id>
</element-citation>
</ref>
<ref id="B115-jpm-08-00044">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reijn</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Abdo</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Schelhaas</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Verbeek</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>CSF neurofilament protein analysis in the differential diagnosis of ALS</article-title>
<source/>J. Neurol.
          <year>2009</year>
<volume>256</volume>
<fpage>615</fpage>
<lpage>619</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-009-0131-z</pub-id>
<pub-id pub-id-type="pmid">19296046</pub-id>
</element-citation>
</ref>
<ref id="B116-jpm-08-00044">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.-A.</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>T.T.-H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K.-C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>Y.-L.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W.-K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>K.-C.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>C.-Y.</given-names>
</name>
</person-group>
<article-title>Construction and analysis of the protein-protein interaction networks for schizophrenia, bipolar disorder, and major depression</article-title>
<source/>BMC Bioinforms.
          <year>2011</year>
<volume>12</volume>
<issue>Suppl. 1</issue>
<fpage>S20</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-12-S13-S20</pub-id>
<pub-id pub-id-type="pmid">22373040</pub-id>
</element-citation>
</ref>
<ref id="B117-jpm-08-00044">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasco</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Corcia</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Veau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vourc’h</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Emond</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pradat</surname>
<given-names>P.-F.</given-names>
</name>
<name>
<surname>Praline</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e13223</elocation-id>
<pub-id pub-id-type="doi">10.1371/annotation/2c2f8fce-a5be-40a3-af8f-48f119b2c593</pub-id>
<pub-id pub-id-type="pmid">20949041</pub-id>
</element-citation>
</ref>
<ref id="B118-jpm-08-00044">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasco</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nadal-Desbarats</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pradat</surname>
<given-names>P.-F.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Antar</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Veyrat-Durebex</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Devos</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mavel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Emond</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Untargeted 1H-NMR metabolomics in CSF: Toward a diagnostic biomarker for motor neuron disease</article-title>
<source/>Neurology
          <year>2014</year>
<volume>82</volume>
<fpage>1167</fpage>
<lpage>1174</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000000274</pub-id>
<pub-id pub-id-type="pmid">24587475</pub-id>
</element-citation>
</ref>
<ref id="B119-jpm-08-00044">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobrowolny</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aucello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rizzuto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Beccafico</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mammucari</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boncompagni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bonconpagni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Belia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wannenes</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Skeletal muscle is a primary target of SOD1G93A-mediated toxicity</article-title>
<source/>Cell Metab.
          <year>2008</year>
<volume>8</volume>
<fpage>425</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2008.09.002</pub-id>
<pub-id pub-id-type="pmid">19046573</pub-id>
</element-citation>
</ref>
<ref id="B120-jpm-08-00044">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocha</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Pousinha</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Correia</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Sebastião</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Early Changes of Neuromuscular Transmission in the SOD1(G93A) Mice Model of ALS Start Long before Motor Symptoms Onset</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e73846</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0073846</pub-id>
<pub-id pub-id-type="pmid">24040091</pub-id>
</element-citation>
</ref>
<ref id="B121-jpm-08-00044">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kempf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boda</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>J.C.F.</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grande</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kaelin</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ristic</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Schmandke</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schmandke</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tews</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Control of Cell Shape, Neurite Outgrowth, and Migration by a Nogo-A/HSPG Interaction</article-title>
<source/>Dev. Cell.
          <year>2017</year>
<volume>43</volume>
<fpage>24</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2017.08.014</pub-id>
<pub-id pub-id-type="pmid">28943240</pub-id>
</element-citation>
</ref>
<ref id="B122-jpm-08-00044">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jokic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gonzalez de Aguilar</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Pradat</surname>
<given-names>P.-F.</given-names>
</name>
<name>
<surname>Dupuis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Echaniz-Laguna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dubourg</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Seilhean</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hauw</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Loeffler</surname>
<given-names>J.-P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity</article-title>
<source/>Ann. Neurol.
          <year>2005</year>
<volume>57</volume>
<fpage>553</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="doi">10.1002/ana.20420</pub-id>
<pub-id pub-id-type="pmid">15786457</pub-id>
</element-citation>
</ref>
<ref id="B123-jpm-08-00044">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruneteau</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bauché</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gonzalez de Aguilar</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Brochier</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mandjee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tanguy</surname>
<given-names>M.-L.</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Behin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khiami</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sariali</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients</article-title>
<source/>Ann. Clin. Transl. Neurol.
          <year>2015</year>
<volume>2</volume>
<fpage>362</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.179</pub-id>
<pub-id pub-id-type="pmid">25909082</pub-id>
</element-citation>
</ref>
<ref id="B124-jpm-08-00044">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pesca</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iannaccone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cannistraci</surname>
<given-names>C.V.</given-names>
</name>
<name>
<surname>Corbo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Previtali</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Quattrini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alessio</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients</article-title>
<source/>Biochim. Biophys. Acta
          <year>2014</year>
<volume>1842</volume>
<fpage>99</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2013.10.013</pub-id>
<pub-id pub-id-type="pmid">24184715</pub-id>
</element-citation>
</ref>
<ref id="B125-jpm-08-00044">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez de Aguilar</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Niederhauser-Wiederkehr</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Halter</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>De Tapia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Scala</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Demougin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dupuis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Primig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Meininger</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Loeffler</surname>
<given-names>J.-P.</given-names>
</name>
</person-group>
<article-title>Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model</article-title>
<source/>Physiol. Genom.
          <year>2008</year>
<volume>32</volume>
<fpage>207</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="doi">10.1152/physiolgenomics.00017.2007</pub-id>
<pub-id pub-id-type="pmid">18000159</pub-id>
</element-citation>
</ref>
<ref id="B126-jpm-08-00044">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukund</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Subramaniam</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Dysregulated mechanisms underlying Duchenne muscular dystrophy from co-expression network preservation analysis</article-title>
<source/>BMC Res. Notes
          <year>2015</year>
<volume>8</volume>
<elocation-id>182</elocation-id>
<pub-id pub-id-type="doi">10.1186/s13104-015-1141-9</pub-id>
<pub-id pub-id-type="pmid">25935398</pub-id>
</element-citation>
</ref>
<ref id="B127-jpm-08-00044">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staunton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jockusch</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohlendieck</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Proteomic analysis of muscle affected by motor neuron degeneration: The wobbler mouse model of amyotrophic lateral sclerosis</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2011</year>
<volume>406</volume>
<fpage>595</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2011.02.099</pub-id>
<pub-id pub-id-type="pmid">21354103</pub-id>
</element-citation>
</ref>
<ref id="B128-jpm-08-00044">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blandin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Marchand</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Charton</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Danièle</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gicquel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Boucheteil</surname>
<given-names>J.-B.</given-names>
</name>
<name>
<surname>Bentaib</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barrault</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stockholm</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bartoli</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome</article-title>
<source/>Skeletal Muscle
          <year>2013</year>
<volume>3</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/2044-5040-3-3</pub-id>
<pub-id pub-id-type="pmid">23414517</pub-id>
</element-citation>
</ref>
<ref id="B129-jpm-08-00044">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>W.-S.</given-names>
</name>
<name>
<surname>Barres</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>The role of glial cells in synapse elimination</article-title>
<source/>Curr. Opin. Neurobiol.
          <year>2012</year>
<volume>22</volume>
<fpage>438</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2011.10.003</pub-id>
<pub-id pub-id-type="pmid">22036016</pub-id>
</element-citation>
</ref>
<ref id="B130-jpm-08-00044">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forsberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Marklund</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Brännström</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis</article-title>
<source/>Acta Neuropathol.
          <year>2011</year>
<volume>121</volume>
<fpage>623</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-011-0805-3</pub-id>
<pub-id pub-id-type="pmid">21287393</pub-id>
</element-citation>
</ref>
<ref id="B131-jpm-08-00044">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phatnani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Maniatis</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Astrocytes in neurodegenerative disease</article-title>
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2015</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.1101/cshperspect.a020628</pub-id>
<pub-id pub-id-type="pmid">25877220</pub-id>
</element-citation>
</ref>
<ref id="B132-jpm-08-00044">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpson</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Ince</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Raman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garwood</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Gelsthorpe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Forster</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>F.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microarray analysis of the astrocyte transcriptome in the aging brain: Relationship to Alzheimer’s pathology and APOE genotype</article-title>
<source/>Neurobiol. Aging
          <year>2011</year>
<volume>32</volume>
<fpage>1795</fpage>
<lpage>1807</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.04.013</pub-id>
<pub-id pub-id-type="pmid">21705112</pub-id>
</element-citation>
</ref>
<ref id="B133-jpm-08-00044">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cozzolino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ferri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carrì</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Mitochondria and ALS: Implications from novel genes and pathways</article-title>
<source/>Mol. Cell. Neurosci.
          <year>2013</year>
<volume>55</volume>
<fpage>44</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2012.06.001</pub-id>
<pub-id pub-id-type="pmid">22705710</pub-id>
</element-citation>
</ref>
<ref id="B134-jpm-08-00044">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffy</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Grierson</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis</article-title>
<source/>Neuropathol. Appl. Neurobiol.
          <year>2011</year>
<volume>37</volume>
<fpage>336</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2990.2011.01166.x</pub-id>
<pub-id pub-id-type="pmid">21299590</pub-id>
</element-citation>
</ref>
<ref id="B135-jpm-08-00044">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alves</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Dariolli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jorge</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Monteiro</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Maximino</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Strauss</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Krieger</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Callegaro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chadi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration</article-title>
<source/>Front. Cell. Neurosci.
          <year>2015</year>
<volume>9</volume>
<fpage>289</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2015.00289</pub-id>
<pub-id pub-id-type="pmid">26300727</pub-id>
</element-citation>
</ref>
<ref id="B136-jpm-08-00044">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercer</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Neph</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dinger</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Shearwood</surname>
<given-names>A.-M.J.</given-names>
</name>
<name>
<surname>Haugen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bracken</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Rackham</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Stamatoyannopoulos</surname>
<given-names>J.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The human mitochondrial transcriptome</article-title>
<source/>Cell
          <year>2011</year>
<volume>146</volume>
<fpage>645</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.06.051</pub-id>
<pub-id pub-id-type="pmid">21854988</pub-id>
</element-citation>
</ref>
<ref id="B137-jpm-08-00044">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Cvijanovich</surname>
<given-names>N.Z.</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Freishtat</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Anas</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Checchia</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Shanley</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Bigham</surname>
<given-names>M.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential expression of the nuclear-encoded mitochondrial transcriptome in pediatric septic shock</article-title>
<source/>Crit Care
          <year>2014</year>
<volume>18</volume>
<fpage>623</fpage>
<pub-id pub-id-type="doi">10.1186/s13054-014-0623-9</pub-id>
<pub-id pub-id-type="pmid">25410281</pub-id>
</element-citation>
</ref>
<ref id="B138-jpm-08-00044">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lunnon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Proitsi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lourdusamy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Newhouse</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sattlecker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Furney</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soininen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kłoszewska</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction and immune activation are detectable in early Alzheimer’s disease blood</article-title>
<source/>J. Alzheimers Dis.
          <year>2012</year>
<volume>30</volume>
<fpage>685</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2012-111592</pub-id>
<pub-id pub-id-type="pmid">22466004</pub-id>
</element-citation>
</ref>
<ref id="B139-jpm-08-00044">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Kamalidehghan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Houshmand</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yong Meng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sadeghizadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aryani</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nafissi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Gene expression profiling of mitochondrial oxidative phosphorylation (OXPHOS) complex I in Friedreich ataxia (FRDA) patients</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e94069</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0094069</pub-id>
<pub-id pub-id-type="pmid">24705504</pub-id>
</element-citation>
</ref>
<ref id="B140-jpm-08-00044">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Parrish</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Mangiola</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Finley</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>High-throughput yeast two-hybrid screening</article-title>
<source/>Methods Mol. Biol.
          <year>2012</year>
<volume>812</volume>
<fpage>39</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">22218853</pub-id>
</element-citation>
</ref>
<ref id="B141-jpm-08-00044">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothstein</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Current hypotheses for the underlying biology of amyotrophic lateral sclerosis</article-title>
<source/>Ann. Neurol.
          <year>2009</year>
<volume>65</volume>
<issue>Suppl. 1</issue>
<fpage>S3</fpage>
<lpage>S9</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21543</pub-id>
<pub-id pub-id-type="pmid">19191304</pub-id>
</element-citation>
</ref>
<ref id="B142-jpm-08-00044">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>R.H.</given-names>
</name>
</person-group>
<article-title>Dynamic Meta-Analysis as a Therapeutic Prediction Tool for Amyotrophic Lateral Sclerosis</article-title>
<source/>Amyotroph. Lateral Scler.
          <year>2012</year>
<pub-id pub-id-type="doi">10.5772/32384</pub-id>
</element-citation>
</ref>
<ref id="B143-jpm-08-00044">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Küffner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zach</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Norel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hawe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schoenfeld</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mackey</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hardiman</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression</article-title>
<source/>Nat. Biotechnol.
          <year>2015</year>
<volume>33</volume>
<fpage>51</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3051</pub-id>
<pub-id pub-id-type="pmid">25362243</pub-id>
</element-citation>
</ref>
<ref id="B144-jpm-08-00044">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westeneng</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Debray</surname>
<given-names>T.P.A.</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>van Eijk</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rooney</surname>
<given-names>J.P.K.</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model</article-title>
<source/>Lancet Neurol.
          <year>2018</year>
<volume>17</volume>
<fpage>423</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30089-9</pub-id>
<pub-id pub-id-type="pmid">29598923</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="jpm-08-00044-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>A central concept in the analysis of molecular interaction networks (MINs) is the identification of network modules, or clusters, of interactions that represent a process or pathway relevant to disease. The affected network module may differ between subgroups of a patient population, which could be used to develop personalized medicine approaches. (<bold>a</bold>) A miniature example of a MIN, with three network modules indicated in blue, green, and yellow. Within each module, specific genetic variants or biomolecules, indicated in red, are known to be associated with amyotrophic lateral sclerosis (ALS) pathology. (<bold>b</bold>) ALS subpopulations separated according to which module is affected or dysregulated. (<bold>c</bold>) Potential drug therapies can be tailored to target specific mechanisms within the ALS disease pathway, corresponding to specific patient subpopulations.</p>
</caption>
<graphic xlink:href="jpm-08-00044-g001"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>